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ABSTRACT
Research into novel vaccine methods is becoming increasingly important for the potential
treatment of widespread diseases such as cancer, HIV, and malaria. Members of the Irvine
laboratory have developed a hydrogel and particle-based injectable vaccine with the potential to
treat such diseases. The vaccine aims to elicit a tailored immune response to a particular type of
disease so as to destroy infected or tumorigenic cells in the body and/or develop immunological
memory for future protection against the disease. The purpose of this paper is to analyze the
feasibility of getting such a biomaterials-based novel vaccination method to the market. Topics
such as application potential, efficacy, modes of delivery, storage, patentability, and costs for
producing the vaccine are explored. Finally, a suggested business strategy is outlined, through
which value can be successfully obtained from the novel vaccine.
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1.0 Introduction
Vaccines and other immunotherapies that can provide protection against cancerous
tumors have long been sought by researchers because they have the potential to be much more
effective, have Vfewer side effects, and be more cost-effective than traditional cancer therapies.
Furthermore, with the emergence of biotechnology and new tools for the rational development of
new vaccines, the possibility of developing effective vaccines that have thus far been
unavailable, such as those for HIV, influenza, hepatitis C, and malaria, is becoming a reality.
Recent developments in the Irvine laboratory have demonstrated that, through use of a novel
colloidal micelle vaccine, a tailored immune response can be initiated. Use of this vaccine could
be applicable to cancer and other previously untreated diseases such that infected or tumorigenic
cells in the body can be destroyed. This paper therefore aims to outline the technical, clinical,
and economic challenges associated with moving this system from laboratory research to
commercial clinical application as a case study for the development of clinically-useful novel
biomaterials for vaccines.
2.0. Background
2'. 1 Vaccine Description
Developed in the Irvine laboratory at MIT, the colloidal micelle vaccine is a hydrogel and
particle-based system that aims to elicit a tailored immune response that will destroy infected or
tumorigenic cells in the body and/or develop immunological memory for future protection
against the disease. The vaccine is composed of super-assembled particles containing the
tollowing: (1) a chemoattractant agent, consisting of either macrophage inflammatory protein-
3ct (MIP-3c) or fMet-Leu-Phe (fMLF or fMLP), encapsulated in a polylactide-co-glycolide
(PLGA) microsphere, (2) an antigen encapsulated in hydrogel nanoparticles that are loaded onto
the surface of the PLGA sphere in a super-particle assembly, and (3) an adjuvant maturation
agent, unmethylated CpG DNA, conjugated to the same hydrogel particles.' A diagram of the
covalently-assenmbled particle can be seen in Figure 1.
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Figure 1: Cross-section schematic of injectable vaccine device as super-assembled particle.
2.2 Immune Sv;,tem Activation
The goal of Irvine's vaccine delivery system is to trigger the complete sequence of
cellular/molecular events that are critical for initiation and sustenance of an effective primary
immune response. The fundamental strategy behind the vaccine is to effectively prime the
body's own dendritic cells (DCs) to initiate the necessary immune response. DCs, making up a
subset of antigen-presenting cells (APCs), are characterized by their strong ability to activate
rinave T cells. In a normal immune response, DCs engulf antigen through receptor-mediated
endocytosis, phagocytosis, or micropinocytosis. The DCs convert the antigen into antigenic
peptides that are stored in the endosomal compartments. If the DCs also receive 'maturation'
signals from pathogens, cytokines, or other cells in the local inflammatory environment, they
will export the peptide antigens to their surface in the cleft of multisubunit protein complexes
called Major Histocompatibility Complex (MIC) molecules, upregulate receptors, such as CD80
and CD86, that are required for activation of T cells, and migrate to secondary lymphoid organs,
where they proceed to activate naYve T cells. DCs are the only professional antigen-presenting
cells known to activate both naive CD8+ cytotoxic T-lymphocytes (CTLs), which destroy
infected cells presenting the antigen against which they have been activated, and naYve CD4+
helper T-lymphocytes (THS), which release soluble mediators that initiate a cascade of events that
involves proliferation of macrophages to destroy the antigen. DCs are capable of activating both
CTLs and THS because they internalize exogenous antigens into endocytic compartments and
then transfer them to the cytoplasm; as a result of this transfer, both MHC class II, which
presents antigens processed in the endosomes and activates TH cells, and MHC class I, which
2
presents antigens processed in the cytosol and activates the CTLs, are utilized. 2 The pathways
by which DCs activate both CTL and TH responses are shown in Figure 2.
CTL
Figure 2: Pathway of presentation of exogenous antigen on MHC class I and class II
molecules of DCs. Antigen located in nanoparticles is internalized into phagosomes of the
dendritic cells. A portion of the antigen is released into the cytoplasm, where it becomes
available to the MHC class I molecules, while the rest of the antigen remains in the
cytoplasm, where it is available to MHC class 1I molecules. 2
A successful immune response, culminating in elimination of a pathogen, is accompanied by the
generation of memory T cells, which help monitor future exposure to the specific antigen. 2
In patients suffering from cancer or persistent viral infections, however, the immune
response is often inhibited as a result of both the failure of the environment of the cell to provide
the necessary maturation signals and the non-immunogenicity of antigens expressed by infected
cells. The objective of the novel vaccine, therefore, is to allow for the correct signals to be
transduced in the body by utilizing the natural properties of DCs so as to efficiently induce
protective immunity even when the normal cascade of events has been hindered. To initiate the
primary immune response through the vaccine, several interrelated steps are taken:
(1) The vaccine attracts immature DCs to the injection site using degradable microspheres
that slowly release an encapsulated chemoattractant; as the microspheres go through
controlled degradation, they create a concentration gradient of chemoattractant in the
environment around the device. The MIP-3a and/or fMLP used in the vaccine serve to
control the migration of lymphocytes and dendritic cells to the device; immature DCs
are attracted to the chemoattractant source, as these APCs have a high expression of
both C1CR6, which binds to the chemokines MIP-3a, and the pair formyl peptide (FPR)
3
and formyl peptide-like receptor (FPLR), which bind to the bacterially-derived peptide
fMLP.
(2) The chemoattracted DCs engulf the hydrogel nanoparticles that are released from the
surface of the chemoattractant microsphere as it dissolves.
(3) Enzymes located within the DCs work to degrade the antigen located within the
hydrogel nanoparticles, thereby allowing the smaller fragments to release into the
cytosol. While each person has a particular set of MHC hapotypes, called an HLA
type, that only responds to particular peptides, the use of a protein theoretically ensures
that when the protein breaks down in the DCs, the various peptides will be able to
create the specific antigen necessary to treat the disease for each different patient's
HLA type. After being engulfed and processed, the antigenic peptide will be presented
on the MHC molecules of the DCs.
(4) The maturation signals, provided by unmethylated CpG DNA attached to the hydrogel
nanoparticles, will initiate several important events upon being engulfed, including
downregulation of chemokine receptors specific for immature DCs such as CCR6 and
FPR and upregulation of mature DC-specific chemokine receptors like CCR7.
(5) Once the dendritic cells have matured, they can migrate towards the lymph node to
prime both CD4+ and CD8+ naYve T-cells to respond to the antigen. A diagram of the
basic principles of the assembled super-particle vaccine is shown in Figure 3.
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Figure 3: Schematic representation of chemoattraction, antigen loading, and maturation of
the immature dendritic cells in the area of the implant.
2.3 Procllcing the Vaccine on a Small Scale
2.3.1 Preparation of Chemoattractant Source
Two chemokines, MIP-3ca and fMLP, have been studied by the lab as chemoattractants
for immature D(Cs. MIP-3a is more selective for immature DCs than most chemoattractants, but
it is a full protein and thus both expensive and difficult to store because of its 3-D nature. In
contrast, fMLP is less specific in attraction of inflammatory cells, but is a peptide and is thus
cheaper and more chemically robust.3 Regardless of the chemoattractant chosen, it is
encapsulated in PLGA microspheres. The chemoattractant delivery vehicle is 20pm in
diameter so that the sphere is large enough to avoid phagocytosis by macrophages, which would
eliminate the chemoattractant. Because PLGA is biodegradable over time, the delivery device is
expected to both create and maintain a concentration gradient for 2-3 weeks and protect the
chemokines from proteases and peptidases prior to release. Release rates can be modified by
varying the lactide and glycolide ratio in the copolymer, the copolymer molecular weight, and
tlhe porosity of the polymer matrix. Because of the differences in the chemoattractants, two
5
different processing techniques have been used to prepare the delivery device, including a water
in oil in water (w/o/w) double emulsion and a single oil in water (o/w) emulsion.
To prepare the PLGA microspheres for use with MIP-3a, the double w/o/w emulsion
technique is used. During this process, Bovine Serum Albumin (BSA) is used as a carrier
protein to protect the chemokine, MIP-3a. 300mg of PLGA is dissolved in ml of
dichloromethane (DCM). Likewise, 30-50mg of BSA/chemokine is dissolved in 250l of 5%
w/v polyvinyl alcohol (PVA). Using a homogenizer, both solutions are then emulsified, first
together, and then with the addition of 20ml of 5% w/v PVA solution. The resulting suspension
is stirred overnight at 1000rpm to evaporate the DCM and then centrifuged and washed four
times in water. The microspheres are then lyophilized and stored at 4C until needed.' A
schematic diagram for the preparation of the microspheres using the double emulsion technique
can be seen in Figure 4.
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Figure 4: Schematic diagram for the preparation of microspheres using the double emulsion
solvent evaporation technique. 4
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Unlike the MIP-3a microspheres described above, to prepare the microspheres for the
encapsulation of the highly hydrophobic peptide fMLP, a single o/w emulsion technique must be
used. To do so, I mg of fMLP is dissolved with 200 mg PLGA in ml of DCM. Using a
homogenizer, the solution is emulsified in 20 ml of 5% w/v (aq) PVA solution. Similar to the
double emulsion technique, the suspension is stirred at 1000 rpm overnight to evaporate DCM,
centrifuged and washed four times, and then lyophilized and stored at 4C.l This process is
shown in Figure 5.
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Figure 5: Schematic diagram for the preparation of microspheres using the o/w emulsion
solvent evaporation technique. 5
2.3.2 Preparation of Antigen Delivery Source
The antigen used for the vaccine is dependent upon the disease treated. Once chosen, the
antigen is encapsulated in hydrogel nanoparticles that are synthesized from poly(ethylene oxide-
b-propylene oxide-b-ethylene oxide) (PEO-PPO-PEO) triblock copolymer, pluronicT M F-68, and
rnethacrylate monomers poly(ethylene glycol) methacrylate (PEGMA), methacrylic acid (MAA),
and poly(ethylene glycol dimethacrylate) (PEGDMA). The smaller size of the hydrogel
particles, 500nm, ensures that these nanospheres are able to be phagocytosed by DCs without
disrupting cellular function.6
The hydrogel particles are produced using a salting out-based miniemulsion
polymerization technique. To do so, 16g of sodium chloride is added to 50ml of 4% (w/vol)
aqueous pluronic TM F-68 and stirred until dissolved. The solution is then degassed with nitrogen
for 15 minutes, after which 50mg of antigen is stirred into the solution. 300mg of PEGMA,
15mg of PEGDMA, and 15mg of MAA are all mixed and degassed with nitrogen and then
7
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stirred into the pluronic/protein/salt solution. The solution is heated in a hot water bath to 400 C,
causing phase separation/emulsion formation as a result of the pluronic copolymer salting-out.
Polymerization is then initiated by the addition of I Omg of both ammonium persulfate (APS) and
sodium metabisulfite (SMS). The resulting particle suspension is diluted with 50ml of deionized
water, and the particles are collected by centrifugation. The gel particles are then washed,
resuspended in 5ml of 0.4% w/vol pluronicTM F-68 and stored at 40C.6
2.3.3 Preparation of Maturation Agent Delivery Source
To ensure that the antigen and the dendritic cell maturation agent are delivered to the
DCs simultaneously, the two agents are delivered by the same hydrogel nanoparticle. The
maturation agent chosen by members of the Irvine laboratory is unmethylated CpG DNA.
Electrostatic assembly is used to bind CpG oligonucleotides to the surface of the hydrogel
particles. 6
To assemble CpG on the hydrogel particles, 10mg of the hydrogel particles are incubated
with 5mg/ml of poly-L-arginine at 370C and shaken overnight. The particles are then centrifuged
and washed four times to remove unbound polycation. In order to provide CpG
functionalization, the particles are resuspended in ml PBS, mixed with CpG oligos, and
incubated for 3 hrs at 37°C. The particles are then pelleted by centrifugation. 6 The processes for
creating the finall hydrogel particle, as discussed in this and the previous section, are shown in
Figure 6.
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Figure 6: Schematic diagram of hydrogel particle synthesis and functionalization with CpG
oligonucleotides. 6
2.3.4 Final Preparation of the Super-assembled Particles
In order to allow for the correct temporal and spatial activation of DCs, the
chemoattractant source, antigen source, and maturation agent are all assembled as demonstrated
in Figure 1. Thus, to prepare the super-assembled particles, 5mg of chemoattractant particles are
incubated in 0.1 N NaOH at 37°C for 30min and then washed with PBS. The particles are then
incubated for 2 hours with 20mg of the hydrogel particles containing the antigen and maturation
agent. 0.1g of EDC is added, and the solution is incubated overnight. The super-assembled
particles are then washed in PBS, lyophilized, and stored at 40C.
2.4 Lalboratorv Results
Initial laboratory studies by Zhao et al.3 and Jain et al.6'7 of the colloidal micelle vaccine
have concentrated primarily on the individual development of: (1) appropriate controlled release
of a suitable chemokine, and (2) delivery of maturation signals and antigen through use of a
hydrogel carrier.
To investigate the controlled release of chemokines from the vaccine, PLGA
microspheres encapsulating either formyl-Nle-Leu-Phe-Nle-Tyr-Lys (fN'LN'YK) peptides or
NIIP-3a were studied in vitro. Using videomicroscopy migration assays, the investigators
detected strong chemotaxis of DCs through 3D collagen gels toward the PLGA microspheres for
9
at least 8 hours. Slow release of chemokine from the microspheres was found to provide
significantly stronger attraction compared to the delivery of freely diffusing chemoattractant, and
results indicated that the microspheres could provide prolonged attraction of DCs from up to
500pm from the source. These results were promising, as the microspheres allow defined
amounts of chemnokine to be delivered to known sites with known release kinetics.6
To study the hydrogel antigen/maturation agent delivery particles, murine bone marrow-
derived DCs were incubated with fluorescent hydrogel particles for 1 hour, washed to remove
unbound particles, and imaged by fluorescence microscopy. DCs were demonstrated to
efficiently phagocytose the gel particles.6 To measure the efficacy of presentation of antigenic
peptides to the T cells through use of the hydrogel particles, DCs were incubated and pulsed for
4 hours with the CpG-modified hydrogel particles. Results indicated that the hydrogel particles
efficiently delivered antigen into both the MHC class I and MHC class II antigen presentation
pathways and provided DCs with the ability to activate naive CD8 + and CD4 T cells.6
Additional findings include those resulting from animal experiments in which antigen particles
were injected subcutaneously, and the immune response was examined by recording the
proliferation of adoptively transferred T-cells. Results indicated that injected particles did not
cause local or systemic toxicity and that both CD4+ and CD8+ T-cells were activated by this
delivery system in vivo. 7
Thus, initial laboratory results have shown significant potential for the novel colloidal
micelle vaccine. Future research plans include supplementary research into the various
individual components of the vaccine. As satisfactory results are obtained, the focus will shift to
analysis of the vaccine as a whole.
2.5 Setting the Stage: Prior Work
The Irvine vaccine was developed both concurrently and based upon the work of several
different investigators. While there are hundreds of studies related to the development of
biomaterials-based vaccines, the work most closely related to rvine's colloidal micelle vaccine
is summarized below.
In 1997, through experiments in which dendritic cells were cloned using transduction and
supertransfection, Shen and coworkers established that antigen delivered in an immobilized form
on small particles, rather than in soluble form, increases antigen presentation on both MHC class
10
I and class II by up to two orders of magnitude because antigen is released in both the cytosol
and the endosornes.8 Researchers in Irvine's lab therefore use physically immobilization of the
antigen on the hydrogel nanoparticles so as to most effectively trigger the immune response.
Sparwasser et al., in 1998, found that bacterial DNA CpG causes simultaneous
maturation of immature DCs and activation of mature DCs, thereby transforming immature DCs
into mature, professional APCs. Researchers demonstrated that it is only in this mature stage
that DCs can express the full complement of co-stimulatory molecules, adhesion molecules, and
antigen-presenting MHC molecules required for effective T cell activation. 9 Based upon these
results, researchers in the Irvine laboratory chose to use CpG DNA as a maturation agent for the
implant.
In 2000, Yang et al. performed chemoattraction studies in which it was discovered that
immature DCs have a high expression of the formyl peptide receptor (FPR) and formyl peptide-
like receptor (FPLR), which correspondingly bind the chemokine fMLP.10 Likewise, in 2001,
Perez-Canadillas et al. found that immature DCs have a high expression of CCR6, which binds
to both chemokines MIP-3a and human 3-defensins." Therefore, researchers have examined
both fMLP and lMIP-3a as chemoattractant sources for the colloidal micelle vaccine.
Finally, Kumamoto et al., in 2002, constructed a device made from poly(ethylene-co-
vinyl)acetate (PEVA) in which the chemoattractant MIP-3[3 and a tumor-associated antigen were
contained. The implant was shown to chemoattract mature DCs and load them with antigen, thus
providing an effective protective response against tumors in mice.12 The vaccine device being
developed in the Irvine laboratory, while similar to the general ideas explored by Kumamoto et
al., is designed to attract immature DCs rather than mature DCs, as immature DCs provide a
more potent immune response because they have higher antigen uptake capabilities. Researchers
on the colloidal micelle vaccine have also chosen to use degradable PLGA microspheres over
nondegradable ['EVA rods because implantation and retrieval are not practically efficient for a
vaccine, and degradation of the Irvine device allows for controlled release of DC-specific
chemokines, which better mimics the chemoattractant gradients generated in situ in natural acute
infections.
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2.6 Distinguishing the Colloidal Micelle Vaccine
Despite the presence of a number of competing technologies in the vaccine field, the
colloidal micelle vaccine is novel and distinguishable in several ways and should meet three
objectives that are not successfully met in current vaccines: The vaccine should (1) utilize
immature DCs to obtain efficient antigen loading; (2) assemble DCs specifically at the
vaccination site in order to achieve a strong, prolonged response; and (3) provide both the
antigen and the maturation signal in a coupled manner so as to prevent tolerance and
autoimmunity. 
It is also expected that the colloidal micelle vaccine will uphold the qualities of an ideal
xvaccine. 13 The vaccine should thus:
elicit a high level of long-lived efficacy and stimulate protection within two weeks of
administration. It should also require only one or two closely-spaced doses to provide a
therapeutic effect.
* be potentially administered without use of a needle and syringe, as oral, nasal, or
transcutaneous delivery have been shown to be the safest modes of delivery.
* be safe for use in all populations, including the elderly and immunocompromised
subjects. It should also be able to be administered in combination, or coadministered,
with other vaccines.
· be producible in formulations that are resistant to high and low temperatures and thus
remain free from stringent storage requirements.
· be able to be manufactured on a large scale through fairly uncomplicated and economical
processes.
In order for the vaccine being developed in Irvine's laboratory to become commercialized, these
important qualities, as well as several other significant aspects of the vaccine's marketability,
need to be explored. Therefore, both the potential to take these steps, and the progress towards
marketing the vaccine, are discussed throughout the rest of the paper.
3.0 Marketing the Colloidal Micelle Vaccine
3. 1 Potential Applications
The colloidal micelle vaccination technology, as mentioned previously, is applicable for
the prevention and/or treatment of numerous diseases, such as cancer, HIV, influenza, hepatitis
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C, and malaria. The potential market size for this vaccine, therefore, is startling. For instance,
the total number of new cases of cancer diagnosed in the United States in 2005 is anticipated to
be about 1,372,910, while 570,280 American deaths are expected this year as a result of cancer.14
In addition, an estimated 5-20% of the US population contracts the flu every year.' 5 There are
also about 35,000 new cases of HIV each year in the United States. 16 Similarly, there are nearly
35,000 cases of Hepatitis C every year in the United States.l7 These applications exist not only
in the United States, but also worldwide, both for the diseases already discussed and for other
infections, such as malaria, that do not generally inflict the United States.
Developing vaccines for cancer and other infectious diseases is an important research
area. For the application of the colloidal micelle vaccine, cancer and HIV encompass two of the
most promising and marketable applications because no successful vaccine has been discovered
to date for either disease, and these diseases are two of the most serious health issues worldwide
today.
3.1.1 Application to HIV
Despite the obvious need for an HIV vaccine worldwide and the potential application of
the colloidal micelle vaccine for such treatment, several considerations make it unlikely that the
Irvine vaccine will be used to treat HIV. Investment in both the public and private sectors for
HIV vaccine research and development has always significantly lagged the need. The reason
behind this lag, and the same rationale that deters investigators from using the colloidal micelle
vaccine for the treatment of HIV, is that preclinical and clinical trials for the prevention of HIV
are extremely costly and difficult. In order to perform a clinical trial on a prophylactic HIV
vaccine, a large population would have to be administered the vaccine and then monitored to
determine if the prevalence of HIV is significantly smaller for those who received the vaccine
than for the control group. Securing participants for such a study, in which the subjects may or
may not develop the disease, is a huge undertaking. The low incidence of HIV in industrial
countries would make for large, expensive trials of uncertain statistical outcome. And while the
incidence rate o HIV is higher in developing countries, significant political and infrastructural
barriers make performing clinical trials there nearly impossible. 18
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3.1.2 Application to Cancer
Although more feasible than development of an HIV vaccine, therapeutic vaccines for
cancer have yet: to attain widespread success. While there are over 200 cancer vaccines in
development, none, apart from the prophylactic vaccine against hepatitis B, have been approved
for use in the United States.9 ' 20 The need for a successful therapeutic cancer vaccine is great
because the improved treatment efficacy, site-specific administration, and reduced adverse side
effects that would be associated with cancer vaccines are desirable over the qualities of standard
cancer treatments. Therefore, the focus of the rest of this paper will be on using the colloidal
micelle vaccine for the therapeutic treatment of cancer.
The molecular hallmark of cancer is genetic instability, which is a consequence of
deletion and/or mutational inactivation of genome moderators. In addition to the numerous
mutations that occur during tumorigenesis, many genes that are generally inactive or expressed at
low levels in the normal tissue are activated during carcinogenesis. Although uncontrolled
growth is a universal biological characteristic of all tumors, the major features of malignant
cancers that cause morbidity and mortality are the ability of the cancer cells to invade across
natural tissue barriers and to metastasize, both of which are linked to dramatic interference with
normal tissue architecture.19
As with many infectious diseases, a cancer vaccine is especially important because the
immune system often does not react to tumors as foreign or dangerous, and thus does not mount
a strong attack against them. There are several reasons for the body's inability to respond to
cancerous tumors. In particular, because the body's DCs do not differentiate between the
pathogen-specific or the self antigens that they take up at the site of inflammation, tolerance
mechanisms have been developed by the body's immune system in order to limit the possibility
of inflammation inducing an attack on the body's own healthy cells. Through these tolerance
mechanisms, the activation of T cells corresponding to pathogen-encoding antigens are favored,
while the activation of the T cells corresponding to self antigens, called trouble-prone
autoreactive T cells, is severely limited. As tumor cells largely express self antigens, a very
weak immune response is instigated against the tumor that typically has no overall effect on
tumor growth.2'
From a vaccination perspective, there are two types of cancer. One type of cancer is
associated with viral infections, such as primary hepatocellular carcinoma, due to hepatitis B
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virus infection, or B-cell lymphoma, which is linked to HIV-1 infection. The second type of
cancer, which includes cancers such as melanoma, involves the development of spontaneous
tumors that express endogenous tumor antigens. 22 The treatment of these two types of cancer
through vaccination can be very different. Whereas with the first type, it is potentially possible
to develop a prophylactic vaccine against the virus causing the cancer, prophylactic treatment is
nearly impossible for use against the second type.
3.1.3 Treatment of Cancer using the Colloidal Micelle Vaccine
The novel vaccine being developed in the Irvine laboratory has the potential to be used to
amount an effective therapeutic immune response against the second type of cancer discussed in
the previous section - that is, against cancers that involve the development of spontaneous
tumors that express endogenous tumor antigens. The concept of vaccination against such
cancers is based primarily on studies demonstrating that immune responses, although weak, can
be mounted against over-expressed self-tumor antigens in cancer patients. Thus, these antigens
have become ideal targets for vaccination strategies.:3 In addition, investigators now more
clearly understand that the environmental context in which antigen is presented plays a
significant role in how the immune system responds. That is, if a pathogenic infection occurs in
the absence of' appropriate inflammatory reactions, pathogen-specific T cells will not be
activated despite the presence of pathogen-specific foreign antigens. In contrast, if autoreactive
T cells are activated as a result of an inflammatory response, a tumor-specific immune response
should be triggered.' The purpose of the colloidal micelle vaccine, therefore, is to combine
these two aspects-presentation of self-tumor antigen and activation of DCs- in order to trigger
a complete immune response against tumor-based cancers.
3.1 .4 Focusing on Melanoma
In order to provide a succinct analysis regarding the possibility of bringing the novel
colloidal micelle vaccination technique to the market, it is necessary to concentrate on only one
type of cancer, as the type of antigen used, the competing markets, the cost analysis, etc. will all
vary from one type of cancer to the other. In many cancer vaccination strategies, melanoma is an
appealing target because melanoma tumors express numerous strong tumor-specific antigens.' 4
In addition, the majority of the successful cancer vaccination clinical trials have been based on
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the treatment of melanoma. Therefore, the application focus for the colloidal micelle vaccine
will be on treating melanoma.
Melanoma is a cancer that begins in the melanocytes of the skin. As shown in Figure 7,
melanocytes are present in the epidermal layer of the skin.
Figure 7: Diagram of human skin. 14
Melanocytes serve to produce the pigment melanin, which gives the color to skin and helps
protect the deep layers of the skin from dangerous effects of the sun. Although melanoma
develops in the melanocytes, it has a high probability of spreading to other parts of the body and
can be a very severe form of cancer.' 4
Skin cancer is the most common of all types of cancers. Although melanoma only
accounts for about 4% of skin cancer cases, it is the cause of about 79% of skin cancer deaths.
The number of new cases of skin cancer in the United States continues to increase yearly, and the
American Cancer Society has predicted that in 2005, about 59,580 new cases of melanoma will
arise in the United States. In addition, it is estimated that there will be about 7,770 American
deaths as a result of the disease.' If the market is expanded worldwide, the number of cancer
patients diagnosed per year becomes nearly 3.4 million.?5 The importance of finding a
therapeutic vaccine for melanoma, therefore, is critical.
16
Basal cell . --- ---- Hair follicle Sweat gland
Lymph vessel
--..
I
,
3.2 Efficac1' of the Colloidal Micelle Vaccine
Crucial to the development of any vaccine is that it is able to elicit a long-lived, high
level of efficacy. One of the fundamental problems with cancer vaccines to date, however, is
that they have shown little, if any, anti-tumor efficacy. As suggested in earlier sections, the
fundamental reason for the lack of tumor immunogenicity is the inability of the growing tumor to
activate the immune system, not the absence of tumor-rejection antigens. In fact, because all
tumors still express specific antigens, these antigens can be used as a basis for activating the
immune system against the cancerous tumors. And once the immune system is activated, it
should be able to recognize and destroy the tumor. Thus, a successful vaccine, including the
novel vaccination technology of the Irvine laboratory, should be able to use specific antigens to
artificially activate the immune system against melanoma, or other types of cancer, in order to
eradicate the disease in a patient.
There are four principal concerns to consider in designing effective cancer vaccines,
including how to: (1) identify potent tumor rejection antigens, (2) stimulate an effective
antitumor immune response, (3) avoid autoimmune pathology, and (4) prevent immune
evasion. 2 These four issues will be discussed throughout the rest of this section.
3.2.1 Choosing the Correct Antigen
In order for the colloidal micelle vaccine to have the potential to be effective, the correct
antigen must be chosen. Tumor antigens, particularly melanoma antigens, can be divided into
three major categories: patient-specific mutated self antigens, shared non-self antigens, and
tissue-specific antigens. The first category of antigens, mutated self antigens, come about as a
result of somatic mutations in normal gene products, which imitate the genetic instability of
tumor cells. These antigens develop randomly and are supplementary to the oncogenic process
in each cancer patient. However, mutated tumor antigens are patient-specific and are therefore
not highly practical for use in vaccination strategies. In contrast, however, the second group of
antigens, shared non-mutated antigens, is well-characterized and better understood for use in the
vast majority of cancer patients. These shared antigens consist of non-mutated molecules that
are over expressed in many cancer cells, but are not highly expressed in typical cells. These
antigens are often not recognized as self antigens because they were never presented efficiently
to the immune system, such as those antigens expressed during fetal life. The final type of
17
antigen is the tissue-specific antigen, which are shared antigens that attack the entire tissue in
which the tumor lies. One obvious disadvantage in using any type of shared antigen is that they
correspond to normal gene products and thus have either already triggered some tolerance or
have the potential to cause autoimmunity, making their use for vaccination sometimes difficult. 21
2'6,37
In general, a good tumor antigen should have several important characteristics: the
antigen should be highly immunogenic and non-self to avoid tolerance and autoimmunity, it
should be presented by as many types of tumors as possible to offer broad applications, it should
not be presented effectively by noncancer cells, and it should contain multiple antigenic epitopes
both to ensure the vaccine's applicability to a broad patient population and to prevent immune
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escape of tumor variants.' Numerous tumor antigens containing most of these traits have been
either isolated from cDNA libraries or deduced from peptides on the surface of tumor cells, and
researchers have identified many of these tumor-associated antigens in melanomas.22 Examples
of antigen possibilities for treating melanoma include the inactivating mutation in
cylindependent kinase 4 (CDK4), the MAGE-family antigens, tyrosinase, gp100, and MART1
(Melan-A).' 9 '2' Possibilities to enhance the efficacy of the vaccine include delivery of multiple
antigens concurrently or finding a "universal" antigen, such as telomerase, survivin, or OFA,
which have the potential to treat many types of cancer.'
While further clinical research would undoubtedly have to be performed to determine the
best antigen for the colloidal micelle vaccine, there are several promising possibilities to consider
for use in the treatment of melanoma. Although tissue-specific antigens, or melanocyte-specific
antigens, can induce tolerance or cause vitiligo, a skin disorder that results in patches of
unpigmented skins as a result of an attack on the body's melanocytes, these antigens have shown
the highest probability for success.' 9 Therefore, the tissue-specific melanoma antigens, such as
tyrosinase, tyrosinase-related protein I (TRPI), TRP2, gp100, and MARTI, may be the best
starting point in the path towards choosing the best antigen for the Irvine vaccine.
3.2.2 Stimulating an Effective Anti-Tumor Response
Whether or not an effective anti-tumor response is stimulated through the vaccination
strategy is dependent upon the degree to which the immune response is induced and how long it
endures in the patient. Of significant importance is the length of time that the immune response
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persists; in cancer patients in particular, a weak, sustained immune response can be more
advantageous than a strong, but short-lived response. Mechanisms such as the induction of a
potent TH-cell response can extend the timescale of the immune system's response to
vaccination.7
Through use of the colloidal micelle vaccine technology, the tumor antigens are expected
to be channeled directly into the DC-presentation pathway and therefore provide an immediate
immune response. Likewise, because the vaccine technology uses controlled degradation to
release the chemoattractant for up to three weeks, the immune response should be stimulated for
sufficiently long periods of time, thereby resulting in a potent immune response. Consequently,
the novel technology has the potential to stimulate an effective anti-tumor response.
3.2.3 Avoiding Autoimmunity
Autoimmunity, or an immune response against the body's own tissues, can be a serious
concern in the development of cancer vaccines. If severe autoimmune disease develops, the
vaccine cannot be effective in improving the health of those suffering from cancer. The
fundamental principle of any cancer vaccine strategy is that there exists a period of opportunity
in dealing with the autoimmune pathology in which a therapeutic antitumor response can be
initiated without undesirable levels of autoimmunity against normal gene products. As described
in earlier sections, however, the vaccination strategy most commonly used against cancer is to
provide effective and possibly repeated vaccinations to activate T cells and thus produce a
strong, natural immune response that can prevail over the immune system's natural tolerance
mechanisms. This increase in the body's immune response severely intensifies the probability of
inducing autoimmune pathology, as an antitumor immune response is expected to eliminate all of
the cells that present the antigens against which the T cells have been activated. The threat of
autoimmunity is particularly severe if self-antigens are used, and autoimmune disease in normal
tissues has been observed in animal models and has also been suggested by melanoma patients
who have developed vitiligo. 2 ' 26
While autoimmunity reactions in the skin can be somewhat insignificant in comparison to
the effects of skin cancer itself, researchers in the Irvine laboratory have developed an important
mechanism through which autoimmunity can be avoided. By coupling the antigen and the
maturation factor in the same hydrogel particle, the sequence of events that occur during a
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normal immune response is better mimicked, thereby helping to avoid autoimmunity.' 28 That is,
if a dendritic cell matures, but receives no antigen, results have shown that the matured dendritic
cells can trigger a response against the body's own cells. 29 In contrast, when the two signals are
coupled, as in the Irvine vaccine, this autoimmunity can be avoided.
3.2.4 Protecting from Immune Evasion
Because cancerous tumors are inherently genetically unstable, the ability of tumor cells to
evade the immune system through a host of genetic means is astounding. Thus, a major concern
in developing effective cancer vaccines is the ability of the tumor to mutate and evade the
immune response altogether. The lack of pro-inflammatory mediators that induce maturation of
DCs, in conjunction with the abundant antigen presentation by tolerizing tumor cells, can often
cause inactivation of tumor-specific T cells and lead to tolerance. As the Irvine vaccine
attempts to initiate and mimic the body's own immune response, tolerance can be a challenge in
mnaking the vaccine effective. Thus, raising a protective immune response against cancer
antigens requires first abrogating the body's tolerance mechanisms.
Similar to autoimmunity, the threat of immune evasion can be reduced by choosing the
correct type of antigen. For example, non-self antigens should have triggered little or no
tolerance previously and could thus be vital in protecting from immune evasion. Strategies such
as immunizing using several antigens concurrently could also be one way to overcome tolerance
possibilities. In addition, tolerance may not be an inherent threat if a potent enough immune
response can be stimulated, as is one of the objectives of the novel vaccination technology.
Finally, because, the novel vaccine technology couples both the antigen and the maturation factor
on one hydrogel particle, tolerance, like autoimmunity, can be better avoided. 126 That is, if the
two signals were not coupled, thus allowing dendritic cells to receive antigen, but not maturation
signals, the correct immune response would not be triggered, allowing the body time to develop
tolerance against the antigen.29 In contrast, when the two signals are coupled, the body is
protected from immune evasion.
3.3 Mocles of Devliver,
Any vaccine can potentially be delivered through numerous methods, including
intravenous, intra-arterial, intraspinal, intrasseous, intra-articular, topical, subcutaneous,
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transdermal, and mucosal. The site of administration can greatly influence the performance of a
vaccine, both because the local tissue environment varies throughout the body, and because
different DC populations will be recruited to the vaccine depending upon the site of
administration. Biocompatibility and efficacy will thus vary depending upon the mode of
delivery used for the vaccine.5 Apart these two important issues, various delivery methods can
still have significant advantages over others. As such, the optimum delivery methods for the
Irvine vaccine will be examined in this section.
3.3.1 Safety of Delivery Methods
While most vaccines in current practice are needle-based, an ideal vaccine would be
administratable without injection. In developing countries, injection safety can be a significant
challenge, as nonsterile needles and syringes can transmit blood-born pathogens, such as HIV
and HCV, as well as leading to other serious diseases. 31 To avoid the potential reuse of needles
and syringes, WIHO developed the "autodisable syringe," which cannot be used more than once.
This syringe is now essential to WHO's universal vaccination policies. 32 However, proper
disposal of any needle-containing device, including the "autodisable syringe" developed by
WHO, can be a challenge.' 3 As such, the needle-free vaccination is still attractive.
Various kinds of equipment have been developed recently in order to avoid the use of
needles and syringes while still using injection-like devices. Both single-dose injector devices
that are capable of delivering liquid or dry powder vaccines through the skin under high pressure
and spring-powered liquid injection devices are being tested in the clinic. Similarly, the "needle-
lite" device uses miroprojection arrays to disrupt the outer layers of the skin and deliver the
vaccine to the epidermis without pain or inflammation at the delivery site. Unfortunately, none
of these devices have obtained broad acceptance, and their high costs make implementation,
particularly in the developing countries, a daunting task. 3' Therefore, the more standard, and
more probable, mechanisms of needle-free delivery, including mucosal and transcutaneous
methods, will be discussed further in the next section.
3.3.2 Types of 'Vaccination Methods
Mucosal administration of vaccines includes oral and intranasal immunization. Several
orally administered vaccines are already commercially available, all of which are based on live-
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attenuated organisms, including polio, Salmonella enterica, and Vibrio cholerae vaccines.33
While oral delivery has been known to induce tolerance in many instances, mucosal
administration is expected to be advantageous as a result of its ease of administration, reduced
adverse effects, and the potential for frequent boosting. Mucosal administration has also been
demonstrated to enhance the immunogenicity of a vaccine. Furthermore, this type of
administration is very attractive for promoting mucosal immunity, as is necessary for protection
in diseases such as HIV. Unfortunately, however, mucosal vaccines have thus far been difficult
to develop, as protein, peptide, polysaccharide, and DNA antigens are extremely labile and can
be significantly degraded in the gut if not protected well.31
Transcutaneous immunization through use of topical vaccine patches, which involves the
application of an antigen with an adjuvant to intact skin, is currently being vigorously
investigated. Through this method of immunization, reagents enter the epidermis, where they are
taken up by Langerhans' cells (LCs), a class of dendritic cells.22 These patches, like mucosal
delivery mechanisms, have shown an enhanced ability to increase the immunogenicity of a
vaccine, as LCs demonstrate a high ability for antigen uptake.34
Both mucosal and transcutaneous immunization would be valuable in developing
countries, where access to health care professionals is often limited and reuse of needles is a
common problem. However, like those methods discussed in the previous section, further
development will have to be made before these methods of vaccine delivery can become a
reality. The attributes of various vaccine development strategies, including the potential to be
delivered needle-free, are shown in Table 1. Note that the Irvine colloidal micelle vaccine, most
likely a combination of the "nonliving antigen delivery systems" and the "new adjuvants," would
be expected to have moderate to high potential for being delivered through a needle-free
mechanism, although the hurdles associated with doing so may be too burdensome to overcome
in the near future. These issues will be discussed further in the following section.
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'Table 1: Attributes of various vaccine development strategies and methods of administration of vaccines 13
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Significantly, for oral delivery to be effective, the colloidal micelle vaccine must be able
to srvive the low acidity in the stomach and the digestive enzymes in the stomach, and it must
colloidal micelle vaccine, currently sized at 20plm, does not fall within the boundaries of either
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of these successful routes. Furthermore, collective experimental evidence suggests that
encapsulation of vaccines in microparticles is unlikely to result in the effective development of
oral vaccines. Thus, while some microparticles continue to show promise as delivery systems
for intranasal immunization, including success using PLG microparticles with absorbent surfaces
for both protein antigen delivery and encapsulated DNA, delivering the Irvine colloidal micelle
vaccine through mucosal routes could be an obstacle far too large to realistically overcome any
time soon.3 3 '35
Transcutaneous delivery of the colloidal micelle vaccine could be an attractive approach
to delivery, as it would provide direct contact of the antigen with LCs, a powerful type of APC.
Unfortunately, the outer layer of the epidermis, called the stratum corneum (SC), provides a
significant barrier to penetration. The SC can be breached through hair follicles and sweat ducts,
or by disruption of the fragile layer such that the superficial cell layers in the epidermis can be
reached. 36 Particular adjuvants, such as the heat-labile enterotoxin (LT), have been demonstrated
to enhance the efficacy of transcutaneously delivered vaccines. CpG has even been shown to
augment the immune response to co-applied antigens.37 Researchers have also demonstrated that
PLGA microparticles can be efficiently delivered into the epidermis using optimized, permeation
enhancing, topical formulations. As would be expected, however, the investigators determined
that particle penetration increased with decreasing particle size.38 While transcutaneous could be
promising for Irvine's colloidal micelle vaccine as a result of the penetration-enhancing effects
of CpG and the efficient transcutaneous delivery of some PLGA particles, no transcutaneous
vaccine has yet to shown strong efficacy. As such, developing a transcutaneous delivery
mechanism for the colloidal micelle vaccine, while an exciting possibility like the mucosal
delivery mechanism, is improbable for the immediate future.
Because use of both mucosal and transcutaneous delivery methods for the colloidal
micelle vaccine would require overcoming numerous challenges, the subcutaneous injection
currently used is the most likely delivery route for a commercialized product. However, it is
important that these delivery methods are kept in mind during commercialization, as they do
have several important safety advantages. Of course, the needle-free injection devices discussed
in section 3.3.1, though expensive, are also a promising possibility for safe delivery of the
vaccine.
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3.4 Sfev of the Colloidal Micelle Vaccine
One of the most significant challenges in developing a new vaccine is to achieve strong
immunogenicity without increasing 'reactogenecity' 3 - that is, to keep the vaccine safe while
still making it effective. Obviously, safety of the patient is of utmost importance, and a benefit-
risk analysis must be conducted to determine the relative importance of efficacy and safety. As a
result of this balancing tradeoff, the safety of any pharmaceutical product is defined by the FDA
as "the relative freedom from harmful effect to persons affected directly or indirectly by a
product when prudently administered, taking into consideration the character of the product in
relation to the condition of the recipient at the time. 39"
Establishing the safety of a vaccine requires preclinical research and testing, clinical
studies, and postlicensure assessments. Responsibility for ensuring the safety of a product lies
with vaccine researchers or manufacturers, regulatory authorities, and other government and
international aencies. 40 General pharmaceutical safety regulations are covered in various
statutes, including the U.S. Code of Federal Regulations, World Health Organization (WHO)
Guidelines, Federal Drug Administration (FDA) Guidelines, International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
(ICH) Guidelines, and European Agency for the Evaluation of Medicinal Practice (EMEA)
Guidelines. 4 ' As a result, two years is generally considered a minimum in obtaining product
licensure in the United States.4 ' And while two years was considered standard for getting
approval in the 1950's, an average of 10 years (see Table 2) is generally required today to
achieve product licensure as a result of the increasingly stringent requirements set forth by the
FDA.
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Table 2: Average vaccine development time per product 18
Time 2.4 2.0 1.8 1.4 1.1 1.3 Total 10
years
Market enince 22% 39% 54% 68% 98%probabilities %
No. candidates in 4 6 2,5 1.9 1.5 1-'
pipeline'
n- 591 :andidates between 1993 and 1994
Fox large pharmaceutical firms S>360 milion sales
AdditKotnJ post marketing ats has increased regulatory and licensng costs rn line with Phase 3 rals
3.4.1 Product Licensure
Vaccines are regulated as biological products in the United States. In order to be
licensed, a vaccine must consist of a "preparation of known characterization and purity that has
been demonstrated to be safe and effective.42" Prior to beginning on the licensing pathway,
several preclinical tests must be conducted. Trials in appropriate animal models are generally
required for evaluating disease pathogenesis, immune response, toxicity, and efficacy.' The
process for manufacturing the vaccine at a research scale must be successfully and safely scaled
up for commercial use. Therefore, all steps in the processing, including production, purification,
and testing, must be approved, as well as the facility in which the vaccine is produced 4 1, which
will be discussed more in Section 3.6.2.4. Tests for sterility, general safety, identity, potency,
and purity of the vaccine are also required for licensing.40
In the United States, when a new vaccine is to be first tested in humans, the vaccine
sponsor or manufacturer must submit an Investigational New Drug (IND) application to the
FDA. The IND application must include information on the manufacturing method, composition
of the vaccine, source of materials, safety, purity, potency, and preclinical studies demonstrating
safety and activity. 42 The clinical pathway for the development and approval of vaccines then
consists of four phases, meant to effectively evaluate both the safety and efficacy of a product.
Phase I studies are the earliest studies conducted in humans. These studies are meant to
purely evaluate the safety of the vaccine and are performed in a small number of healthy adults,
usually consisting of between 10 and 100 subjects. As a result of the small sample size, only
very common adverse effects can be identified. Follow up must occur at a minimum of 3 days
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postvaccination and again after 1 month. Any adverse effects discovered must be documented
by case report forms. Results from phase 1 studies, if even mildly serious, can halt further
clinical testing. 1'041'42
Phase 2 studies are much larger than those of Phase 1 and involve the participation of
several hundred, individuals. The goal of Phase 2 clinical trials is to further evaluate the safety of
the vaccine, and both local reaction and general side effects are well documented. Another
objective of Phase 2 studies is to determine the optimum dose and schedule required to maximize
the immune response generated. During this Phase, researchers often include blinding,
randomization, and placebo controls. Although significantly more in depth than Phase I studies,
Phase 2 studies can often only identify the most common of adverse effects. 40,41,42
As both Phase 1 and Phase 2 trials are intended to establish the safety of a pharmaceutical
product, Phase 3 studies are larger trials meant to establish efficacy in the target population at the
expected dose range and formulation. The sample size for Phase 3 is determined by the number
of subjects required to establish efficacy of the new vaccine and can thus range from a few
hundred to tens of thousands of subjects. Phase 3 trials are randomized and controlled. One of
the most significant objectives of these studies is that they are designed to help assess the overall
benefit-risk relationship of the vaccine for licensure.4 0'41' 42 While historically, this benefit-risk
analysis has been informal, formal methods of analysis, including cost-benefit calculations, have
recently been developed and incorporated into the vaccine decision-making process.4 °
After all three phases of clinical development are successfully completed, and efficacy
and safety have been established during preclinical and clinical development, a biologics license
application (BLA) can be submitted to the FDA. n the United States, both the manufacturer and
the FDA submit their findings to the Vaccines and Related Biological Products Advisory
Committee (VRBPAC), an external committee of experts, for approval. If approved for
licensure, a further safety regulation requires that a product label be produced to describe both
the vaccine's proper use and the potential benefits and risks of using the vaccine. 40
Postlicensing, regulations still maintain that safety, potency, and quality consistency are
continued. Thus, Phase 4 postmarketing studies, conducted in the first few years after licensure,
are intended to further investigate lower frequency adverse effects and to focus on issues that
might have arisen during prelicensure testing. In addition to Phase 4 studies, monitoring of
vaccine safety is continued after licensure through surveillance of spontaneous adverse event
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reports made to vaccine manufacturers or directly to the FDA. These reports are analyzed using
the Vaccine Adverse Event Surveillance System, which relies on reports from healthcare
providers and patients, and can be potentially useful for detecting unrecognized adverse side
effects, monitoring known reactions, identifying possible risk factors, and vaccine lot
surveillance. 4 ° Finally, safety regulations require that any changes regarding the vaccine
postlicensure be validated and reported.4 0'4'
3.4.2 Possible Adverse Effects Associated with the Colloidal Micelle Vaccine
As with the development of any pharmaceutical product, there are various
biocompatibility concerns associated with the novel Irvine vaccine. Associated particularly with
cancer vaccines is the concern that they may cause autoimmunity, as discussed in Section 3.2.3.
Therefore, the cancer vaccine must illicit an immune response against cancerous cells without
harming the body's own cells. Of course, ensuring that the vaccine causes as few side effects as
possible is also a primary concern when developing a new product. The most common adverse
effects linked to vaccines with adjuvants, such as the Irvine vaccine, include tenderness and
swelling at the inoculum site. These effects can occur as a result of: (1) contamination of the
vaccine during formulation; (2) instability of the vaccine during storage; (3) formation of
inflammatory immune complexes at the inoculation site; and (4) poor biodegradability of the
adjuvant vaccine resulting in prolonged persistence in the tissue.43 Promisingly, CpG has been
shown to be a much more tolerant adjuvant than many others and has actually been demonstrated
to be one of the most promising adjuvants to augment immune response with minimal toxicity
and side effects.44
Despite the possible toxicity associated with the development of any adjuvant vaccine, it
is expected thatl regardless of the side effects that ensue, it will still prove to be safer than
traditional cancer treatments, including chemotherapy, surgery, radiation, or various
combinations of the three. Chemotherapy, or drug therapy that is used to kill cancer cells, can
cause nausea and vomiting, hair loss, fatigue, anemia, and increased chance of bleeding or
infection. Likewise, surgery, used to remove tumors from the cancer patient, can cause pain
during recovery., temporary nausea from anesthesia, and the potential for bleeding or infection.
Finally, side effects for radiation therapy, which uses an external beam of x-rays, gamma rays or
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alpha and beta particles directed at the tumor to destroy cancer cells, include loss of appetite,
skin changes, and fatigue.4 5
3.4.3 Obtaining FDA Approval for the Colloidal Micelle Vaccine
All of the synthetic materials used to produce the colloidal micelle vaccine have been
FDA-approved as components of various other drugs and devices. While this approval may
make licensing the colloidal micelle vaccine slightly easier, however, it will still be necessary to
go through the approval process in order to get FDA approval for the delivery technique. Thus,
the safety of the vaccine as a whole, including use of the vaccine adjuvants, will need to be
approved by the! FDA before commercial marketing of the vaccine is possible.
Unfortunately, while many adjuvants have been developed over the past 75 years, few
have been accepted for routine vaccination as a result of either their immediate toxicity or a fear
of delayed side effects.43 In 1997, Chiron's MF59 adjuvant o/w emulsion, used in conjunction
with the influenza vaccine, became the only adjuvant to be licensed in the world for human use
in addition to aluminium salts.46 However, PLGA has been approved for use in a variety of
biomedical purposes, including use as a controlled release delivery system for the therapeutic
protein human growth hormone.31 Similarly, Lupron Depot is marketing the FDA-approved one-
month injectable microspheres of PLGA containing leuprorelin acetate for the treatment of
endometriosis and prostate cancer.5 Researchers thus believe that getting PLGA approved for
use as a vaccine adjuvant should not be a hindering factor in obtaining licensure for a new
vaccine. Similarly, PEG, the primary component of the hydrogel nanoparticles, has proven non-
toxic and has been approved by the FDA for use in other foods, cosmetics, and
pharmaceuticals. 47 Therefore, using PEG hydrogel nanoparticles as a vaccine adjuvant should
again not cause significant delay in receiving FDA approval for the novel Irvine vaccine.
The biological materials and adjuvants used in the vaccine, however, could present a
larger hurdle for obtaining FDA approval of the Irvine vaccine. The use of systemically
administered chemokines is limited clinically as a result of the high potential for toxicity
associated with such use.48 Often, doses of cytokines that induce tumor regression in mouse
models can be lethal in humans. However, the use of cytokines aimed at DCs rather than T cells
has shown much more promising signs of inducing an immune response without creating high
levels of toxicity.48 Thus, the MIP-3a or fMLP used in the vaccine should potentially be safe for
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use in humans, although clinical trials obviously have to be conducted to ensure the safety of the
vaccine. Similarly, the maturation factor, CpG DNA, has been tested in several clinical trials,
and results of Phase I studies have shown that CpG is safe and can demonstrate positive
immunostiumlatory effects that increase with higher doses.4 9 However, CpG has not yet been
approved for use by the FDA. Finally, depending upon the antigen used for the vaccine, it could
be difficult to get FDA approval as a result of the side effects associated with various antigens.
Despite the various components of the Irvine vaccine that could potentially make FDA
approval of the vaccine a challenge, there is promise. While the current attitude towards
vaccination favors vaccination safety over efficacy when a vaccine is delivered to a healthy
population of children and adults, when high-risk groups, such as patients with cancer, are
involved, an additional level of toxicity is often considered acceptable if the benefit of the
vaccine is substantial.4 3 And while most clinical trials for cancer have not yet been successful,
there is always the prospect that a well-developed product, such as the novel Irvine vaccine, will
be quickly approved for use as a cancer vaccine.
3.5 Storage Reqtirements
As discussed in section 2.6, an ideal vaccine should be resistant to ambient conditions so
that wide distribution, particularly to Third World countries, can be achieved. In fact, the
commercial success of a pharmaceutical product is often related to its ability to remain stable and
sterile during storage.5 Unfortunately, because the colloidal micelle vaccine contains proteins,
researchers believe that it must be refrigerated at 4C even in its lyophilized form. Therefore,
methods of delivering such a vaccine to developing countries through the 'cold chain,' as well as
possible alterations to the processing technique to allow for ease in storage, are explored in this
section.
3.5.1 Stability during Storage
The storage conditions can be of utmost importance to the stability and shelf life of a
polymer-containing pharmaceutical product. If stored in a humid atmosphere, a polymer
microsphere, such as the PLGA or PEG nanoparticles used in the Irvine vaccine, can absorb
water. The absorbed moisture can then react with the biodegradable linkages of the polymer,
causing degradation and a change in the physiochemical properties. These changes can then
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affect the vaccine's reactivity upon injection. The presence of residual oligomers, monomers, or
polymerization catalysts or solvents can increase the potential for moisture adsorption or
degradation. The relative strength of the water-polymer bonds and the degree of crystallization
can also be important factors in the stability of the vaccine during storage. While PLGA and
PEG are reported to be stable to moisture absorption at atmospheric pressure if free of
contaminants, studies of these polymer particles have shown that storage at such atmospheric
conditions can still induce crystallization, which in turn can severely affect the properties of the
polymer. 5
Of course, problems can also arise as a result of the presence of biological materials in
the vaccine. If temperatures get too high or low, the protein antigen can easily denature, possibly
making the vaccine ineffective upon injection. Similarly, interactions between the protein and
the polymer matrix, such as adsorption processes and ionic interactions, can result in instability
of both the protein antigen and the polymer matrix. 33 Thus, all of these stability issues must be
considered when determining the optimum storage conditions for a vaccine.
3.5.2 The Cold Chain
As a result of the various modes through which a vaccine can become unstable, one of
the most severe challenges in commercial vaccine development is proper handling and storage of
the vaccine until its delivery, particularly in developing countries. Currently, the United
Nation's Children's Fund (UNICEF)'s Expanded Program on Immunization (EPI) provides
routine immunization to populations at risk through both fixed health centers and mobile
outreach centers. However, to do so, vast amounts of financial and human resources are
necessary in order to maintain the stability of vaccines by storing and transporting vaccines at
recommended temperatures from the point of manufacture to the point of use.'3 The system used
to maintain the efficacy of the vaccine over time is called the "cold chain," which consists of a
series of storage and transport links, all of which are designed to keep the vaccine at the correct
temperature until it reaches the patient. 50 A typical vaccine cold chain system is shown in Figure
8.
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The World Health Organization (WHO) and UNICEF product information sheets (PIS) detail the
immunization equipment that is necessary to meet WHO 'cold chain' specifications. 32 Thus, the
recommended equipment both for storage, including cold rooms, refrigerators, freezers, and for
transport, including cold boxes and vaccine carriers, must comply with a set of performance
standards defined by WHO and UNICEF. Stock management procedures must also be followed
to ensure that vaccines are not stored longer than necessary at all levels of the cold chain. Most
important among the PIS are the temperature specifications for storage. While the stability of
EPI-recommended vaccines varies depending upon the antigen, the EPI requires that storage
equipment maintains temperatures between 2 and 8C to avoid instability of the vaccine. These
requirements can be a huge obstacle for developing countries, where access to electricity is often
limited. Of course, also required to efficiently carry out the 'cold chain' operation, aside from
obtaining the proper equipment, are personnel to manage both the maintenance of the equipment
and the vaccine distribution. These 'cold chain' requirements can be a huge financial burden,
often making developing countries a rather unappealing market for vaccine manufacturers.
3.5.3 Methods to Increase Stability of the Irvine Vaccine during Storage
The Irvine vaccine is currently stored at 4C, which is within the standard temperature
range of vaccines distributed by the EPI. However, because the microencapsulated vaccine is a
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dried formulation, it is possible that the vaccine may actually be amenable to storage without
refrigeration, as some proteins in their dried state can be more stable than in solution
formulations. This theory, of course, would have to be well studied before risking ambient
storage conditions. 3 3 Furthermore, despite this possibility, exploration should be made into
making the vaccine more amenable to non-stringent storage requirements. For example,
'glassification' technologies, which consist of drying vaccines in the presence of sugars such as
trehalose or other stabilizers, can provide vaccines that are resistant to extreme temperatures.
Although clinical trials have not been performed on formulations created by 'glassification,' if
trials show success, the technology could relieve pressure on the 'cold chain.' 13 Thus, there are
various storage possibilities available for consideration, at least one of which should ensure that
the Irvine vaccine is able to be successfully stored for delivery.
3.6 Large-Scale Development (o'the Colloidal Micelle Vaccine
As mentioned in section 2.6, one of the most important characteristics of a novel vaccine
is that it is able to be manufactured on a large scale. For production on a large-scale to be
successful, however, intellectual property rights, manufacturing processes, cost analysis, and a
feasible business plan must all be fully examined and developed. The rest of this section
therefore focuses on these four important aspects of vaccine development.
3.6.1 Intellectual Property
Intellectual property is crucial to the development of any new technology. It is essential
to both to the survival of companies and the pursuit of innovation. In addition, intellectual
property rights guarantee companies an acceptable, long-lasting return on research activities.
Patent rights in the field of vaccines, however, have been severely weakened in the eyes of
vaccine manufacturers over the past twenty years. One significant blow includes the early
introduction of generics as a result of the "Bolar" Provision. Prior to this provision, the courts
had held that clinical testing of a copy drug before the expiration of the original patent so as to
accelerate FDA approval of the copy drug was an infringement of the patent. However, in the
Drug Price Competition and Patent Term Restoration Act of 1984, the "Bolar" Provision allows
generic drug producers to market and manufacture their goods as soon as the existing patent
expires. 52 Similar acts have been passed across the world. Another blow to vaccine intellectual
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property includes compulsory licensing, linked to the bioterrorism scare; governments across the
world now have the right to produce a patented product or process without the consent of the
patent owner for public, non-commercial purposes. 52 Additional problems arise abroad because
numerous foreign countries are not able to successfully enforce patent laws.
Advances in maintaining vaccine patent rights worldwide have been made to some
extent, however, by extending patent laws to allow for new indications and orphan products.
Similarly, the Patent Term Restoration Act of 1988 prolongs the life by up to five years of those
patents claiming a human drug product, medical device, food additive or color additive, in order
to compensate patent holders for marketing time lost while developing the product and awaiting
government approval.53 Thus, despite the hindrances associated with the development and
patenting of vaccines, government officials have begun to take steps to ensure that intellectual
property rights are kept sufficiently effective.
3.6. 1.1 Distribution of Intellectual Property
In general, the vaccine industry is dominated by a small number of multinational firms,
including GlaxoSmithKline, Aventis Pasteur, Wyeth, and Merck, as shown in Figure 9.
Green Cross (1
Bio Farmna (1
Serum Institute d Indria (1'
Figure 9: Companies that cover most of the vaccine market.' 8
Merck, Wyeth, Aventis, and GlaxoSmithKline have increased their coverage of the vaccine
market over the past 20 to 30 years; their share of the market rose from approximately 50% in
1988 to nearly 70%/o today.' 8 Smaller companies and companies abroad take in the remaining
revenue in the vaccine market. Despite this monopoly over the vaccine market, most of the
34
patents related to Irvine's vaccine are primarily owned, at this point, by non-profit cancer
research institutes or small, developing pharmaceutical companies. However, following market
trends, most of these patents are likely to end up licensed to a larger corporation for profitable
marketing.
3.6.1.2 Patent Search
The intellectual property rights concerning the colloidal micelle vaccine of the Irvine
laboratory involve a couple of different aspects. Namely, the compositions and methods for
making both the chemoattractant and antigen/maturation particles have to be examined. In
addition, the use of particular biological materials, such as the specific maturation factor,
chemokine, and antigen used for the vaccine, should be investigated. While a few strictly
foreign or international patents (i.e. for inventions not patented in the United States) are available
that are related to the vaccine of the Irvine laboratory, most of the pertinent patents in the field of
pharmaceuticals., particularly vaccines, are in effect in the United States. Therefore, the focus of
the rest of this section will be only on the relevant United States patents.
3.6.1.2.1 Patents Related to Chemoattractant Particle
The compositions and methods for producing the PLGA chemoattractant particle
component of the vaccine have been well patented. The patent that stands out most in the area is
U.S. Patent No. 5,330,768, assigned to MIT, in which the inventors use as an example the
identical process used to create the PLGA chemoattractant particle. Claiming a method for
controlled release and a method for forming microspheres using a group of various polymers,
including PLGA, the inventors cover a broad range of polymeric microspheres for drug
delivery. 4 A couple of similar patents, including U.S. Patent Numbers 4,225,5815 ' and
4,269,82150' also disclose the use of biodegradable microspheres made of PLGA to deliver a
bioactive agent, but they have since expired and thus do not prohibit manufacturing of the
colloidal micelle vaccination method. Thus, in order to use the PLGA chemoattractant particle
for the colloidal micelle vaccination method, either cross-licensing would have to occur, or
production of the vaccine would have to be deferred until Patent No. 5,330,768 expires in 2011.
Because PLGA particles are patented so well, researchers in the Irvine laboratory might
have better luck ensuring exclusive rights to a chemoattractant delivery system if a different
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encapsulation technique is used. One encapsulation technique that might be worth examining
further is the use of anionic hydrogel materials. For instance, alginate cross-linked with calcium
might provide an effective release mechanism, as the microsphere would dissolve over time as
the anionic alginate and cationic calcium strands slowly untangle and separate. A quick patent
search suggests that microspheres made of these anionic hydrogels may be more easily
exclusively commercialized than the PLGA microspheres, though an in depth search would
certainly be necessary before such changes to the vaccine design could be considered.
3.6.1.2.2 Patents Related to Antigen Particles
In contrast to the chemoattractant particle, the nanoparticle containing antigen and
maturation agent has the potential to be successfully patented, as it is the most novel aspect of
the Irvine vaccine. As such, a patent application has been filed by members of the Irvine
laboratory to cover those aspects of the colloidal micelle vaccine not previously patented by
other inventors. In the application, the inventors make 66 total claims, all of which are related to
three primary aspects of the vaccine. First, they claim "a composition for modulating an immune
response against an antigen in a mammal," which includes a hydrogel particle consisting of a
hydrogel polymer, an immunogen encapsulated in the particle, and a ligand on the surface to
provide an activation signal to the antigen presenting cell. In conjunction with this claim, the
inventors claim a particle containing chemoattractant that can be conjugated to the hydrogel
particles through carbodiimide coupling. The second aspect claimed by the inventors is "a
method for enhancing an immune response to an antigen in a mammal," where the method
consists of administering a therapeutically effective amount of a hydrogel particle containing a
hydrogel polymer, antigen, ligand to react with a dendritic cell, and a pharmaceutically
acceptable carrier (i.e. chemoattractant PLGA particle). And finally, the inventors claim "a
method of suppressing immune response to an antigen in a mammal," by administering a
therapeutically effective amount of the same hydrogel particles.57 Because only the treatment of
cancer is being evaluated in this report, the final primary claim, concerning autoimmune disease,
will not be further discussed. However, this aspect could be important to consider when the time
comes to further expand the market of the colloidal micelle vaccine.
Unfortunately, a couple of patents in this area have the potential to heavily block the
colloidal micelle vaccine from easily coming to the market right now. United States Patent
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number 5,008,116, titled "Immunostimulatory Microsphere," claims an invention that involves
the use of a carrier or adjuvant to induce a therapeutic immune response to an antigen. The basic
invention involves a macroporous polymeric microsphere in which antigens are entrapped in the
particle. The patent discloses several aims of the invention similar to those of the novel
vaccination method from Irvine's laboratory, including bringing about a stronger, longer lasting
immune response, targeting the interaction of the antigen to specific classes of cells, inducing a
therapeutic response to a weak antigen by providing an improved carrier for the antigen, and
providing a slow release mechanism for the antigen to prolong the contact of antibody and
lymphocytes. The primary claim of the inventor is "a macroporous microsphere compromising a
particle and an antigenic component... wherein said antigenic component is physically entrapped
in or chemically crosslinked, to the interior of said particle, said particle being comprised of a
polymer.x8" The colloidal micelle technique from the Irvine laboratory could infringe upon this
patent in a couple of ways, depending upon how the claims are interpreted. The specific claims
of the patent are very broad, claiming rights to a microsphere made of a material 'selected from
the group consisting of a biopolymer, synthetic polymer, carbohydrate,5 " and more. Thus, while
the patent does not specficallv claim the hydrogel particle developed by the Irvine laboratory, it
does broadly cover concept of an antigen-containing particle. Therefore, in order to avoid
infringing this patent, either cross-licensing would have to occur, or the novel vaccine would
have to be brought to the market after the patent expires in 2008.
Similarly, United States Patent Number 6,312,731, titled "Rapid Release Encapsulated
Bioactive Agents for Inducing or Potentiating an Immune Response and Methods of using
Thereof," and assigned to both the Southern Research Institute and Corixa Corporation,
describes an invention that involves a delivery system capable of effecting a CTL response to
less immunogenic antigens.5 9 Previous patents by the same inventors and owned by the same
companies, numbers 6,024,983) and 5,075,10961, claim similar inventions. The goal of the
invention, like the novel vaccine of the Irvine group, is to effectively provide compositions of an
antigen encapsulated in particles that will rapidly release the antigen once taken up by cells and
thus elicit a strong CTL response. Overall, the inventors claim a broad method of inducing or
potentiating a CTL response in a subject, the methods of administration for doing so, and the
composition for doing so. The primary claim of the inventors is a method or composition "for
inducing or potentiating a CTL response in a subject, comprising administering to the subject an
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effective amount of a composition comprising an antigen... encapsulated in a polymeric
composition," where the polymeric composition includes a blend of a polymer to provide
structural integrity and "a component selected from the group consisting of a rapidly dissolving
component, a rapidly swelling component, and a component that causes osmotic rupture of the
encapsulated polymeric composition 59" to thus cause an effective immune response, similar to
the hydrogel antigen-containing nanoparticles of the colloidal micelle vaccine. Another concern
with this patent is that it also claims a microsphere that "further comprises a bioactive agent
capable of potentiating the CTL response encapsulated in a second polymeric composition,"
thereby in effect possibly claiming the maturation agent used in the Irvine vaccine, depending
upon interpretation. Thus, in order to avoid this patent, it will most likely be necessary to cross-
license with the group, as waiting for the patent to expire requires holding production until 2018,
by which time that Irvine patent will have only approximately six years remaining years of
coverage until its expiration date.
3.6.1.2.3 Patents Related to Use of the Biological Materials
Not only do the compositions and methods for the particles need to be examined, but use
of the specific materials themselves, such as the maturation factor, chemoattractant, or antigen,
can potentially be patented. For instance, inventors Arthur Krieg and coworkers secured over ten
patents related to CpG, the maturation factor used for the colloidal micelle vaccine. Assigned to
Coley Pharmaceutical Group and/or the University of Iowa Research Foundation, U.S. Patent
Numbers 6,194,388, 6,207,646, 6,218,371, 6,429,199, and 6,653,292 provide broad coverage for
composition of matter and uses of CpG products as immune stimulants for the treatment of
cancer, infectious diseases, and other serious human illnesses. Claims within the patents include
the composition of CpG,62 a method vaccination in a subject through administration of an
antigen and CpG, 6' 3 a method for stimulating an immune response where an antigen is
administered in conjunction with CpG and a cytokine, 64 a method for activating a dendritic cell
by contacting a dendritic cell with CpG,6 5 and a method for increasing the responsiveness of a
cancer cell to therapy using CpG.6 6 As the last of these significant patents was not filed until
1999, use of CpG as used in the Irvine vaccine will be covered until at least 2019. Therefore,
cross-licensing will almost definitely have to occur between the producers of the Irvine vaccine
and Coley Pharmaceutical Group/University of Iowa Research Foundation. Because maturation
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factors aside from CpG are available, it may be worth looking into other possibilities to avoid
these broad patents.
Unlike the use of CpG, both chemoattractants MIP-3a and fMLP each only appear to
have one potentially blocking patent. U.S. Patent Number 6,645,491, assigned to Schering
Corporation, covers use of MIP-3ct as a chemoattractant to modulate the migration of dendritic
cells.6 7 Likewise, U.S. Patent Number 6,017,537, assigned to Connaught Laboratories Inc.,
claims "a method of enhancing the immune response of a host.. wherein the antigen of interest
and the fMLP adjuvant are administered to the host concurrently. 68 " While again, not all aspects
of the Ivine vaccine are covered by either of these patents, cross-licensing might have to occur
in order to obtain the rights to use either fMLP or MIP-3a for the Irvine vaccine. Like the
maturation factor, there is the option to explore the use of other chemoattractant materials to
avoid infringing these patents, although such exploration can be time-consuming and
impractical.
Obviously, the choice of antigen will also affect the intellectual property rights of the
Irvine vaccine. 'Various patents do exist that claim rights to the use of particular antigens for use
in the treatment of vaccines. For instance, U.S. Patent Number 2005/0129715 claims rights to "a
method of inducing an immune response to a tumor... (where the) vaccine strain comprises a
truncated LLO protein fused to an antigen wherein the antigen is expressed on the tumor.6 9" In
this patent, the inventors claim rights to MAGE-1, among other tumor antigens. Similarly, U.S.
Patent Number 2:005/0059056 claims rights to "a method of inducing an immune response in a
subject" through use of gplOO-related proteins and peptides.7 0 Thus, the choice of antigen for
the Irvine vaccine may depend not only on its effectiveness, but also on the availability of patent
rights to the antigen.
3.6.1.3 Intellectual Property Strategy
As demonstrated throughout this section, despite the novelty of the Irvine vaccine as a
whole, there are several patents that, collectively, provide considerable blocking mechanisms to
bringing Irvine's colloidal micelle vaccine to the market. It is important to remember, however,
that vaccines generally take at least ten years to develop from an idea to a marketable product 5t ,
as per Table 2. Estimating that the vaccine will therefore reach the market approximately seven
years fom now (2012), both significant patents 5,008,116 and 5,440,768 should have expired.
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Therefore, only Patent Number 6,312,731, assigned to Southern Research Institute and Corixa
Corporation, and the patents related to the specific materials of use will be left to block Irvine's
technology. While there is always the option to choose different maturation factors,
chemoattractants, etc., much of the device design is covered in Patent Number 6,312,731, which
does not expire until at least 2018. Assuming that the patent application filed by Irvine is
eventually issued, patent rights should last until at least 2024. Therefore, in order to effectively
market the vaccine as specified this far, Irvine would almost definitely have to cross-license with
the Southern Research Institute and Corixa, as well possibly cross-license with the Coley
Pharmaceutical Group and/or the University of Iowa Research Foundation and Schering
Corporation or Connaught Laboratories. Another, probably more practical option, would be to
license the patent to a large pharmaceutical firm, where vaccine production is more tfeasible than
for a small start-up company.
3.6.2 Manufacturing Plan
Large-scale production of the vaccine should theoretically be very different than the
laboratory-scale production described in section 2.3. On a small-scale, vaccine particle
formation occurs predominately with the use of laboratory-scale mixers, homogenizers, or
sonicators, which do not function through the same mechanisms as large-scale batch mixers,
homogenizers ad/or static mixers. As such, there are several variables related to this scale-up
that can affect the processing outcome of the emulsion-based PLGA particles in the colloidal
micelle vaccine. The type of apparatus used to create the emulsion, and specifications chosen for
the apparatus, can highly affect the outcome of the process. The surfactant type and
concentration can also influence the resulting emulsion, as different mixtures of surfactants can
decrease the surface tension of two immiscible liquids by varying orders of magnitude.
Similarly, variables such as the viscosity of the liquids, the density, etc. can have an effect on the
emulsion outcome. In contrast, however, the salting out-based miniemulsion polymerization
technique used to produce the hydrogel particles is primarily dominated by thermodynamics and
]kinetics, and the manufacturing scale-up will have very little effect on the outcome of the
process. Therefore, the focus of this section will be on the manufacturing specifications
necessary to ensure that the PLGA particle is of appropriate quality and size for effective use in
the colloidal micelle vaccine.
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3.6.2.1 Formation of PLGA Primary Emulsion through Homogenization
The initial emulsion step for production of the PLGA particle is performed through
homogenization. Homogenization is an effective mode of emulsifying liquids, particularly when
a small final droplet size is required, and when continuous processing can provide an advantage.
On a large scale, homogenization involves the dispersion of the liquids by forcing the mixture
through a small orifice under very high pressures.71 The orifice ranges in size, but can be as
small as 10 - 4 cm 2. The layout of a standard homogenizer can be seen in Figure 10.
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Figure 10: Schematic of a typical homogenizer7 '
When two immiscible liquids are forced through the small orifices of a homogenizer at
pressures ranging from 3 to 300 MPa, strong shearing forces are set up in the annular space, and
owing to pressure build-up from the flowing liquids, the valve opens against a spring. The
instability of the resulting high speed jet disrupts the liquid into tiny droplets, or
microspheres.71 ':'2 The overall mechanism of microsphere formation thus occurs by first
deforming the interface between the two phases in such a way that droplets form. The droplets
are mostly too large and are subsequently broken up into smaller spheres. Finally, surfactants
are used to stabilize the emulsion.7
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3.6.2.1.1 Controlling the Droplet Size
As discussed previously, a PLGA microsphere of 20pim in diameter is important to
ensure proper functioning of the colloidal micelle vaccine. In order to obtain the correct final
microsphere size, however, the original emulsion diameter must be significantly larger than
20gtm, as the polymers make up only about 3% of the organic DCM phase initially added to the
emulsion. Assuming that MIP-3a is used, rather than fMLP, the aqueous volume makes up 20%
of the initial volume, while the organic phase makes up the final 80%. Thus, assuming that the
aqueous volume remains constant, but that the final organic volume is only 3% of the initial
volume, the initial diameter necessary to obtain a 20gm microsphere becomes 33.tm.
In general, the higher the pressure that is applied to the homogenizer, the less the valve
lifts, and the smaller the droplets become.7 3 The relationship between the pressure of the
homogenizer, ph, and average droplet diameter, d, can be determined using the following
relationship:
d = ph-3 5y 3'5 Cz 2' s (equation 1)
where C is a constant, z is the effective distance in the homogenizer valve over which the
turbulent energy is dissipated, and y is the interfacial tension between the oil and water.72'7 4 The
constant Cz2'5 is approximately equal to 0.25 in S.I. units, but can vary by a factor of about 2.3,
depending on the homogenizer. 72 This equation was derived assuming that turbulent, inertial
forces are the cause of droplet break-up, but still generally applies if flow is dominated by
viscous forces.7
Equation I can thus be used to determine the homogenizer pressure necessary to create a
final microspheres of size 33pm. Assuming both an interfacial tension of 50ON/m, as is typical
for oil/water interfacial tensions, and a constant Cz2' 5 of 0.25, the necessary pressure becomes
approximately 171 MPa. It should be noted, however, the addition of surfactants, such as the
PVA added for creation of the PLGA microspheres, decreases the surface tension by several
orders of magnitude.75 '7 677 Therefore, if a surface tension of .05N/m is assumed, rather than
50ON/m, the required pressure can be as low as 0.2MPa. It is important to note, however, that the
final size of the chemoattractant particles is also significantly dependent upon the static mixer
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used during the secondary emulsion, and the specifications of that mixer will be discussed in
section 3.6.2.2.
3.6.2.1.2 Capacity of the Homogenizer
The time required to form dispersions of the necessary size depends primarily on the
viscosity of the liquids. Assuming again that turbulent, inertial forces dominate fragmentation,
the critical time necessary for deformation of a drop of liquid is given by:
Tdcf = 1r-2,/5p-1 Y-2,5 (equation 2)
where Tdef is the characteristic time for deformation, Tqj is the viscosity of the drop, £ is the energy
density, p is the! mass density of the drop, and y is the interfacial tension.7 4 The time necessary
for disruption of a droplet is a few times that needed for deformation. In homogenizers, this
disruption time is generally <0.lms.
Assuming a droplet viscosity of about .001N/m2, an energy density of 1012 W/m3, which
is common for industrial homogenizers, a mass density of 1,000kg/m3 , and an interfacial tension
value of .05N/m, the time for deformation of one antigen-containing droplet becomes, as
expected, only a small fraction of a second (5ns). The time for disruption of a droplet, therefore,
becomes approximately 15ns.
Because this disruption time is nearly instantaneous, and because the homogenization
process is continuous, the capacity of homogenizers can run as high as 50,000 liters per hour.
The creation of chemoattractant particles for one dose of vaccine requires 20ml of capacity.
Thus, theoretically, it is possible to create 2.5 million doses-worth of microspheres an hour;
obviously, this amount is excessive, and a much lower-capacity homogenizer can be used.
Therefore, both the production time and the capacity of homogenizers should not be limiting
factors in processing the vaccine.
3.6.2.1.3 Choosing a Homogenizer for the Irvine Vaccine
As discussed in section 3.6.2.1.1, use of a homogenizer with less than 171MPa of
pressure is an important first step in production of the chemoattractant particle. Therefore, a
homogenizer similar to the Niro Soavi high-pressure homogenizer, as is shown in Figure 11,
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which can apply up to 1500bar, or 200MPa of pressure, would be able to supply more than
enough pressure to create the particles. The Niro Soavi homogenizer operates continuously, has
been approved for use in the pharmaceutical industry, and can be used successfully with organic
solvents.78
•1 .- s. 
CC
Figure 11: Niro Soavi High-Pressure Homogenizer.78
3.6.2.2 Formation of PLGA Secondary Emulsion through Static Mixing
On a laboratory scale, the secondary emulsion is processed through use of a
homogenizer. Production of the chemoattractant particle on a large scale, however, can be best
carried out through use of a static mixer. Static mixers are made up of a series of geometric
mixing elements enclosed in a pipe. These mixing elements use the energy of the flow stream to
create mixing between fluids.79 80 Two examples of static mixers are shown in Figure 12.
Figure 12:: Arrangement of mixing elements for Left: Koflo Static Mixer, Right: Komax
Static Mixer. 79.81
Mixing by a static mixer occurs through three mechanisms: (1) two-by-two division, in
which each element doubles the number of previous divisions, (2) cross-current mixing where
divided streams are recombined by direct impingement; and (3) back mixing that causes the
down-stream fluid to be mixed with the up-stream fluid.8 ° Static mixers are advantageous
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because they are small in size, have a simple set-up, lack moving parts, can be run continuously,
and are easy to sterilize. In addition, static mixers offer effective control of the microsphere size
and can tolerate a wide range of materials.8 2
3.6.2.2.1 Controlling the Droplet Size
The most important step in controlling the droplet size is the static mixing step. If it is
assumed that the final microsphere diameter is a function of the configuration of the mixer, the
number of elements, and the physical properties of the dispersed phases, dimensional analysis
can be used to analyze various static mixing set-ups. Using this process of dimensional analysis,
Maa and Hsu, in 1996, found a relation that could be used to determine the droplet size of a
microsphere formed using a Komax static mixer in the secondary emulsion step of a double
emulsion process. By using four dimensions, including time, length, mass, and force, Maa and
Hsu derived six dimensionless groups:
`1 = If(11 2, 13, 14, 115, 116) (equation 3)
I = d/O
I1, = aI\/'/gcO-I = Weber number/Reynolds number
13:= lt,/tlo
114 = n
115 - c/p 0
116 = Po/P
where d is the microsphere diameter (cm), 0 is the diameter of static mixer (cm), gp is viscosity
of the aqueous phase (cps), V is the flow rate of continuous phase (ml/s), gc is a conversion
factor ([g cm]/[dyne sec2]), o is the interfacial tension between the organic and aqueous phases
(dyne/cm), po is the viscosity of the organic phase (cps), n is the number of mixing elements, c is
the polymer concentration (g/ml), po is the density of the organic phase (g/ml), and p is the
density of the aqueous phase (g/ml).'s The sixth dimensionless number, 116, was considered a
constant and left out of the final analysis. Using the remaining five dimensionless numbers, the
investigators assumed, based on empirical findings, that the function dependence of equation 3
could be described with a power-product relationship and thus developed the following
equation:8 s
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d/O = a(gaV/gc02o)b(t/o)Cnd(c/p,) ) (equation 4)
Using least squares for regression based on experimental data, the coefficients in equation 4
could be determined, ultimately resulting in equation 5:8°
d = 0.4830 ' 20 2V-0.5 5 6 0.5 5 6 g-0.560 P0. 00 4 n-0.6 6 0 C0 .6 6 3 (equation 5)
Equations similar to equation 5 have also been developed for several other types of static mixers.
However, the Komax mixer has been found to be the most efficient mixer,8 so the remaining
mixers are not discussed in this paper.
Using equation 5, and approximating an interfacial tension of 7.7 dyne/cm, 80 a PVA
viscosity (g) of 0.27 g/cm/s, a PLGA viscosity (o) of 1 g/cm/s, and a polymer concentration of
0.3 g/ml,' the required flow rate and mixer diameter required to form a 20gpm final
chemoattractant microsphere using a Komax static mixer can be determined. Additional inputs
include specifications of the Komax mixer. Each Komax mixer has 21 elements, but several
mixers can be used in a series to large numbers of elements. In addition, the Komax mixer
comes primarily in diameters of /4", 1/2", and ", although larger sizes are available if necessary.
The varying initial velocities necessary to guarantee an initial emulsion diameter of 33gm are
laid out in Table 3.
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Table 3: Theoretical processing for 33gm diameter microsphere synthesis in Komax Mixer
0.0033 0. 635 5.52 7.7 27 1000 21 0.3
0.0033 1 27 24.69 7.7 27 1000 21 0.3
0.0033 2 .54 110.49 7.7 27 1000 21 0.3
0.0033 0. 35 2.42 7.7 7 1000 42 0.3
0.0033 1.27 21.84 7.7 27 1000 42 0.3
0.0033 2 54 48.53 7.7 27 1000 42 0.3
0.0033 6 35 1.50 7.7 27 1000 63 0.3
0.0033 1.27 6. 7 7.7 27 1000 4 ' 0.3
0.0033 2.54 9. 99 7.7 27 1000 632 0.3
0.0033 O. 35 .06 7.7 7 1000 84 0.3
0.0033 1.27 4.76 7.7 27 1000 54 0.3
0.03033 2. 4 21.31 7.7 7 100 54 03.3
As demonstrated by the above results, there are several factors to be taken into account to
determine the optimum static mixer set-up to use for production of the vaccine.
3.6.2.2.2 Capacity of the Static Mixers
Determining the time required to produce one dose of chemoattractant particles for the
vaccine using the static mixer involves a simple calculation. Because the static mixing process is
continuous and the mixer diameter remains constant, the initial flow velocity is equal to the final
flow velocity. Therefore, using the various flow rates from Table 3, and a volume of 20ml per
dose, the time for firmation of the secondary emulsion can be seen in Table 4.
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Table 4: Time for formation of a microsphere of size 33$tm for various set-ups
0J 535 _.52 _ _ 1 Z 3.52
1.27 24.69 21 0.8 
2.54 !10.49 21 O. 1
0.635 2.42 2. 825
1.27 1S0.84 42 1..4
2.54 48.53 2 041
0.635 . 6 3 1336
1.27 .70 e3 298
2.54 29.99 X 3 Q 67
0.,635 !.06 54 1.79
1.27 4 .76 ea 4 20
2.54 21.31 . 4 0.94
As demonstrated above in Table 4, processing one dose-worth of chemoattractant particles,
depending upon the flow velocity, and thus the mixer diameter and number of elements, can take
between 0.18 and 13.36 seconds. Using these numbers, approximately 300 to 20,000 doses of
chemoattractant could be created per hour, depending upon the static mixer used. Thus, because
the highest market share possible would require only approximately 6.8 million doses per year
for the entire melanoma population, the static mixer, like the homogenizer, should not create a
severe limiting step during manufacturing of the colloidal micelle vaccine.
3.6.2.2.3 Choosing a Static Mixer for the Irvine Vaccine
In order to optimize the static mixing process, it is best to have the fewest number of
mixers possible so as to keep the cost of equipment low, the lowest processing time per dose, and
the lowest power usage. In balancing all of these requirements equally, the best static mixing
set-up is to have two 1.27 cm-diameter mixers aligned in parallel. These specifications
correspond to using two of the Komax Mixer Model Number 500-121, which has removable
elements for cleaning and inspection. 8 1 Despite this suggested set-up, however, it should be
noted that the inputs necessary for optimization may not in reality be balanced equally,
,depending on the relative importance of each parameter to the manufacturer.
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3.6.2.3 Vaccine Stability during the Manufacturing Process
A considerable challenge in manufacturing the colloidal micelle vaccine is ensuring both
antigen and microparticle stability.
3.6.2.3.1 Protein Stability
During the manufacturing process, several conditions can lead to protein instability and
denaturation. The preparation of PLGA microparticles requires some exposure of the protein
antigen to the organic solvent DCM, which in itself can cause slight denaturation. Likewise,
antigen instability can arise as a result of the high shear forces necessary for homogenization.
Finally, various stresses that arise during lyophilization can easily lead to protein instability.
However, because the Irvine vaccine, unlike many vaccines, is expected to active both B and T
cells, rather than only B cells, protein instability may not be a significant problem; T cell
receptors, unlike those of B cells, recognize short linear sequences of amino acids that are
associated with MHC antigens, and denaturation may still allow T cells to recognize these short
sequences. 3' Regardless, steps should be made to ensure that the protein antigen is as stable as
possible during the manufacturing process.
3.6.2.3.2 Emulsion Stability
In addition to protein instability, there are several modes of instability associated with the
polymer particles, many of which can lead to changes in the final emulsion size. Although the
addition of surfactants serves to help stabilize the emulsion by both lowering the surface tension
and allowing for the development of interfacial tension gradients do/dz that impede the flow of
liquids along the interface, 72 it is still possible for instability to occur during formation of the
colloidal micellc vaccine. The three most significant modes of instability for emulsions are
demonstrated in Figure 13 and are briefly explained in the remainder of this section.
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Figure 13: Types of instability in emulsion production T
The first type of emulsion instability, creaming, involves the rise of dispersed droplets as
a result of gravitational forces. Creaming occurs in many dilute emulsions if the phases are not
exactly the same density.7' However, this instability should be trivial during processing of the
colloidal micelle vaccine because the DCM solvent is heavier than water, allowing for a counter
force to the gravitational effects that generally cause emulsion droplets to rise to the surface. In
contrast to creaming, flocculation, which occurs when small droplets stick together in three-
dimensional clusters but do not fully coalesce, and breaking, which involves the spontaneous
coalescence of small emulsion droplets into larger droplets,71 could be important during
production of the vaccine microspheres, as both could result in an increase in the PLGA droplet
size. However, these instabilities should be able to be well controlled through the addition of
PVA, which acts as a structural barrier for the droplets.
3.6.2.4 Plant Schematic
A significant consideration for planning a successful manufacturing plant is determining
a feasible large-scale plant schematic. The goal of scaling up a vaccine production process is to
select and combine unit operations that are able to be scaled to the necessary commercial
requirements while still maintaining the advantages of a laboratory-scale process. However,
vaccine production is highly regulated by various statutory requirements. The most restrictive
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regulatory guidelines for vaccine production are laid out in the Good Manufacturing Practice
(GMP) regulations, which guarantee that pharmaceutical products are produced in a consistent
manner and have the appropriate safety qualifications necessary for their intended use. GMP
thus requires that facility design has unidirectional flow of materials, product, and personnel so
that "upstream"' production is separated from "downstream" purification. Production suites are
required to be on separate heat, vacuum, and air conditioning systems that provide classified,
filtered air. "Clean" corridors are mandatory, and entrance and exit from the production areas
must occur through air locked doors. In addition, the equipment used for vaccine production
must be calibrated, validated, and documented to maintain consistent product output. 41
To uphold GMP regulations and maintain a sterile manufacturing facility, an isolator, or a
controlled environment chamber, can be used during septic manufacturing. Connecting the
manufacturing process to an isolator allows the production and handling of the vaccine to take
place in an enclosed, controlled, sterile environment. Figure 14 shows a possible schematic for
the PLGA microsphere emulsification steps. Note that a hardening tank, rather than an
evaporation chamber, is used to harden the microspheres; this process is advantageous at a large
scale because it uses less time and energy to achieve similar results.
scA')9 3
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Figure 14: Possible large-scale production for the colloidal micelle vaccine. The dashed
squares mark components contained within the isolators.8 3
After emulsion formation, the microspheres can be lyophilized in a steam-sterilized
lyophilizer that is coupled to the rest of the manufacturing process by another half-suit isolator,
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which allows two individuals to perform operations simultaneously inside the sterile chamber.
The lyophilizer, process equipment, and isolator must all be placed in a clean room.83 Figure 15
shows a possible large-scale set-up for the overall vaccine production process, based on a
ProLease manufacturing facility used for similar microsphere formation.
LYOpiLZER
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Figure 15:: Possible industrial set-up for production of the colloidal micelle vaccine '8 3
3.6.3 Cost Analysis
3.6.3.1 Vaccine Market
The global vaccine market is growing; from 1992 to 2002, the market grew at an annual
rate of 9% to go from a market size of approximately $3 billion to $6 billion. ' As few as 20
years ago, the market for vaccines was less than $1 billion. However, the market has grown
from a "nonmarket" to a sizable one, as shown in Figure 16. This market increase corresponds
to an increase in vaccine research across the globe, caused by factors including the progress of
medical science that allows for a better understanding of the immune system, a new focus on
therapeutic vaccines rather than preventative, and the emergence of biotechnology and molecular
biology that has lead to better tools for the rational design of new vaccines.51
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Figure 16: Growth of the vaccine market.5 '
As shown above in Figure 16, over the next ten years, the market is expected to continue
to grow at double-digit rates to reach at least $15 billion by the year 2010. 51 Much of this growth
will lie within the group of vaccines called "expanders," which are new technologies for new
disease markets (see Figure 17); the novel vaccine of the Irvine laboratory would be included in
this growing group.
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Figure 17: Expected future growth of the vaccine market.?
The geographical breakdown of the vaccine market is, as would be expected,
concentrated more in North America and Europe than among the "rest of the world," as shown in
Figure 18. North America comprises about 40%/ of the market value of vaccines, a percentage
which is also linked to the higher vaccine prices. Europe and the "rest of the world" make up the
remaining 60%. 5' Numerous organizations are striving to make vaccines available worldwide so
that not only the industrial nations can benefit from new vaccine technologies. Expanding the
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market of a vaccine worldwide, however, can have significant economic consequences, as will
be discussed further in the later parts of this section.
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Figure 18: Global vaccine market geographical breakdown in 2001. s5
3.6.3.2 Vaccine Production
In the past couple of decades, the costs to research, develop, and manufacture a new
vaccine on the global market have exploded due to increased regulatory requirements, and it now
costs $200-$400,M to do so successfully.8 4 In general, there is a set of defined costs that make up
the investment needed to develop, scale-up, and sell a vaccine. These projected costs for
development, based on the typical costs for development of an average vaccine, are shown in
Figure 19. As demonstrated, these costs include the necessary funding required for research,
clinical trials, and manufacturing scale-up that occur in the various stages of vaccine
development. 5 '
Pre-clinical Phase I Phase II Phase III
Iltlnie , Pl tluc t Test i' Proof f * Safet * Don O) Efficacy File g Reglstratio
M)tigens 0ien' Conmepl £ ,ncep!t immuno Safer S',fer,
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Research Phase Earl- Development L[ate Development Registration
Phase Phase Phase
Figure 19: Average vaccine development time and costs for one vaccine.-'
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An estimated and simplified cost analysis for production of the Irvine vaccine in a small
plant is seen in Table 5, which includes materials, labor, and fixed costs. As mentioned
previously, about 59,580 new cases of melanoma are expected to occur in the United States in
2005, and the numbers continue to rise yearly.' 4 Assuming that the vaccine can be marketed
worldwide, however, the number of new incidents of melanoma yearly rises to about 3.4
million.- 5 So as not to overestimate the market that the new vaccine would capture at the outset,
the cost model in Table 5 assumes that there is low demand for the vaccine initially, thereby
assuming that the colloidal micelle vaccine will capture only 1% of the melanoma market at the
outset. The calculations for Table 5 also assume that 10% of the investments can be paid off
each year, that the building is approximately 25,000 sq. ft., and that the fixed overhead is
approximately 15%/O of total costs. Labor, Energy, and fixed costs are estimated based upon
common values in the respective areas. One final significant assumption is that research and
development co)sts for the pre-clinical and clinical phases of vaccine development are
approximately $1 75M; although all research and development costs for each vaccine are
different, this number is reasonable based upon development of other vaccines.l8
Table 5: Cost analysis summary
Material Cost; i: 
Energy Cost
Labor Cost
Static Mixer and Homogenizers
Freezer Room
incubator= .
Lyophilizer 
Fixed Overhead Cost -
Building Cost
Maintenance Cost :
Research and Devetopment
$50000
$0.17 - -!
$0.03 :
$0.01 '
$0.05
$0.11 
$543.14 i
$0.77
$2,0.15 =
$2,573.53 
$34,00c00.
$11,2573 ::
$2o02,0 .00
$2,000.00
$6o00.00
$3,5oo00.00
$7,500.00
$36,933,415.36
$52,500.00 =
$10,000.00 
$175,000,000.00e
0.005% 
0.082% 
0.001% 
o.o000% --
.' 0.001% -
0.003% -
15.000% :0
0.021%0: 
0.004% :::=
71.074% -
Despite the estimated costs in Table 5, there are numerous additional factors that can
influence the cost of producing a vaccine. The scale of operations has a significant impact on the
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cost of manufacturing a vaccine. Vaccine production is, in general, a "fixed cost" business. In
most vaccine manufacturing plants, approximately 85% of cost is made up by the plant,
equipment, research and development, etc., while only 15% of the costs are variable, including
raw materials, e tc. The cost percentages for the colloidal micelle vaccine based upon Table 5 are
shown in Figure 20.
a] Matedal Cost
* Energy Cost
o Labor Cost
o Static Mixer and Homogenizers
* Freezer Room
El Incubator
* Lyophilizer
o Fixed Overhead Cost
* Building Cost
* Maintenance Cost
o Research and Development
Figure 20: Cost drivers for vaccine production with low market demand
As a result of the "fixed cost" vaccine business, the unit cost can fall rapidly with increases in
production volume. In general, if fewer than 100 million doses are produced per plant, a
substantial amount is added to the final cost of one vaccine. s" Because the vaccine will most
likely only capture a fraction of the 3.4 million melanoma population initially, significantly
fewer than 100 million doses will be produced per year, adding costs to the production. Figure
21 shows a graph of unit cost vs. production volume for the vaccine based upon the information
from 'Fable 5. It can be seen that if the market for the vaccine can expand to cover all types of
cancer, which overall affects 100 million people per year, and eventually various other diseases,
the cost per dose of vaccine will lower significantly.
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Figure 21: Graph of Unit Cost vs. Production Volume for Irvine's vaccine
Relying on expensive inputs, such as antigens or other proteins necessary for a cancer
vaccine, can significantly raise the production cost. Producing those same products within the
firm, however, can be extremely cost effective. As shown in Figure 20, the materials cost for
producing the vaccine is nearly 15% of the overall cost to produce for low demand. However,
producing the biological materials within the new company could significantly lower this cost
and thereby reduce the overall cost to produce the vaccine. As a result, any company
manufacturing the colloidal micelle vaccine would most likely choose to follow such a cost-
saving step.
Several other factors are important in determining the cost of production, although none
of them are quite as extensive as those already discussed. The location of the base plant is one
significant issue for vaccine manufacturers. Because industrial countries such as the United
States require higher wages, they can be severely impacted by labor costs. Emerging country
suppliers can have as much as a $0.12 advantage per dose of those manufacturers located in
industrial countries.'8 Because the Irvine vaccine is relatively expensive compared to most
'vaccines, however, this slight increase in cost per dose should not be largely significant, and
producing the colloidal micelle vaccine in the United States would help avoid political and
marketing concerns.
The presentation, or number of doses per labeled pack, can significantly affect the
production costs. This relationship is true because many single-dose vials require the same
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equipment and labor as multidose vials, but yield fewer doses. Overall, using single-dose
packaging as opposed to multi-dosed packaging can increase the "production" price (includes
labor and equipment and glass vials, etc.) by a factor of approximately 2.5. However, because
again, the overall costs for the Irvine vaccine are very high in comparison to the "production"
price, the increase in cost should not be hugely significant. In addition, use of single-dose
packaging is advantageous for safety reasons, as it helps avoid contamination from needle reuse
and reduces the probability of the vaccine going to waste after sitting open for more than six
hours. 8 5
Finally, assuring capacity requirements are met is an obvious way to reduce costs in the
long-run. As a result of the 3-5 year time period that it takes to build a new vaccine production
facility, vaccine manufacturers are forced to make capacity decisions well before the actual
market size is known.86 Because production of the vaccine is based on fixed costs, it is
economically advantageous to build a plant large enough to manufacture the colloidal micelle
vaccine based on large demand for the product. The suggested machines and capacities for
production of the novel Irvine vaccine would therefore be chosen to ensure that capacity
requirements are always met, which, as was shown in Section 3.6.2, should be a fairly simple
matter. Doing so, however, ensures that the costs associated with building additional, higher
capacity plants, are avoided.
3.6.3.3 Pricing the Colloidal Micelle Vaccine
As a result of the high costs associated with vaccine development, high prices per dose
must initially be charged to break even. However, as discussed previously, as the production
quantity increases, lower prices can be charged. Over time, the value of the vaccine decreases as
a result of loss of patent rights and generic production. Despite these challenges, there is a
period of time for which profits can be seen, as shown in Figure 22.
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Figure 22: Vaccine development and uptake. 87
In the vaccine market, tiered pricing is often used, in which lower prices are charged for
vaccines in developing countries relative to those charged in industrial markets. Using this
equity pricing system, vaccine manufacturers can charge a minimal price based on only the
variable costs in poor, developing countries, so as to allow the countries to access the vaccine,
while charging higher prices that cover both the variable and fixed costs in industrial countries in
order to pay off their vaccine development and production costs. As a result of tiered pricing in
the vaccine industry, there is an average price differential of 70x between the poorest and
wealthiest markets, and one dollar is the standard expected price per vaccine for Third World
Countries.8 6 Although this pricing system is beneficial in that it allows important vaccines to be
available globally, it can be a severe burden to the manufacturer to supply the vaccine at such a
low price, while expecting industrial markets to make up the price difference. As such, vaccine
companies often find it difficult to justify to their parent pharmaceutical companies their
involvement in the "marginal" worldwide market.l886
The cost to produce one dose of colloidal micelle vaccine can cost between $891.50 to
$3,620.92, depending upon the production volume. Of course, if higher production volumes are
used, the cost would continue to drop significantly, as demonstrated in Figure 21. As a result of
both the tiered pricing generally used to price vaccines. and the uncertainty corresponding to the
market demand, it is difficult to recommend an optimal price for the colloidal micelle vaccine.
However, prices between $10,000 and $20,000 per dose for industrial countries and
approximately $500 per dose for the poorest countries (enough to cover materials costs) would
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be standard choices for this vaccine, assuming that the vaccine is highly effective. As two doses
will most likely be necessary for complete treatment, these prices will double for the full
treatment cost. Although it is nearly impossible to estimate how tfar globally the new vaccine
would reach, these price ranges should ensure that the vaccine turns a profit. For example, if, in
the first five years, the vaccine was able to capture only a low market (1% of the market), and
500/, of this market was in industrial countries where the cost of the vaccine was set at $10,000,
while 50% was in the lower-income countries where the vaccine was priced at $500, the
expected profit would still be approximately $360M. While it is impossible to run this cost
analysis for all of the possible market and price scenarios, the price ranges specified should
guarantee that the vaccine returns a profit once on the market.
Although the Irvine vaccine will undoubtedly have to be priced at a much higher price
than the average common vaccine, both in First World and Third World Countries, as a result of
the high materials costs associated with cancer vaccination, this price can still be competitive
with other cancer treatment strategies. As discussed in Section 3.4.2, traditional treatment of
cancer typically includes chemotherapy, surgery, radiation, or various combinations of the three.
Chemotherapy generally costs the patient between $25,000 to $65,000 for complete treatment,
although it is not uncommon for costs to exceed that range.8 8 Likewise, surgery can cost
upwards of $10,000. Finally, radiation can range in price from $5,000 to $40,000 depending
upon the type and duration of treatment.89 Even a successful DNA cancer vaccine would be
expected to cost approximately $22,000 per dose, and multiple doses would most likely be
required." Thus, a $20,000 to $40,000 price range for a complete cancer vaccine treatment,
while high for vaccine prices, is still significantly financially competitive with other forms of
cancer treatment and should be a reasonable range within which the Irvine vaccine can be
successfully marketed.
3.6.3.4 Investment Risks
There are, of course, many risks, including scientific, technical, political, and market-
based risks, associated with production of a vaccine that can lead to either the requirement of
significant additional investments or entirely wasted investments. Some of these investment
risks are shown in Figure 23.
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Figure 23: Possible risks associated with the development of one vaccine.' 8
Associated with all of the risks involved in vaccine manufacturing is the problem that
while vaccines provide high value to the human society, the economic value of such vaccines is
often not nearly as incentive as for other pharmaceutical products, as shown in Figure 24.
Worldwide, vaccine sales are approximated to make up only about 2% of the pharmaceutical
market, an amount equivalent to the sales of one successful ulcer drug.9 '
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Figure 24: Social Value vs. Economic Value for vaccine sales. 91
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As a result of the risks associated with vaccine development, most pharmaceutical companies do
not see inherent value in the vaccines business. 91 However, as mentioned in section 3.6.3.1,
there is high potential for cancer vaccines, such as the Irvine vaccine, to create a large, successful
market, generating billions of dollars in revenue. Regardless, only after assessing the risks
demonstrated in Figure 23, as well as any other potential risks, can any company or investor
make an informed decision about whether or not to invest in the product.'"
3.6.3.5 Financing the Colloidal Micelle Vaccine
While it is difficult to attract companies to invest in vaccine research as a result of the
numerous risks involved, the market attractiveness has, at least, increased over the past 10 years
or so (see Figure 25). The establishment of various alliances for vaccine research has increased
investment in new vaccine technologies, and the public sector can often be trusted to contribute
to at least the beginning stages of vaccine research. Foundations such as GATES could have a
huge potential impact on development of a novel cancer vaccine, particularly if the vaccine is
targeted not only at the First World, but also at developing countries; GATES alone has provided
nearly $450 million towards the Grand Challenges in Global Health Initiative with the hope that
new and improved vaccines, among other developments, can significantly improve the health of
populations worldwide.9 2 The potential impact of such organizations will be discussed further in
Section 3.8.1.
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Figure 25: Historical attraction of vaccine investment.9 1
Basic funding for vaccine research and development generally comes from the
government through taxes, profits from sales of other products, and risk capital. Of the $1.4
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billion that fund U.S. vaccine research and development annually, approximately 46% comes
from vaccine sales, 36% from taxpayers and federal organizations, and 18% comes from risk
capital. The economic data available for vaccine research for 1995 is demonstrated Table 6.93
Table 6: Vaccine research and development - Sources of funding 199593
Source Estimated Amount
in Millions
Taxpayers $ 500 (36°,;)
NIH
Intramural
Grants to academia
Other agencies
Vaccine sales $ 650 (46")
Large companies (15 to 20°o sales)
Risk capital $ 250 18',,,)
Smiall companies
'Total $1400 (100'.',)
Thus, as shown in Table 6, in order for the Irvine vaccine to receive funding throughout all of the
stages of development, there are three options, including taking investments from government
funding or other foundations, finding enthusiastic venture capitalists, or licensing to a large
pharmaceutical company. A suggested optimal business plan will be discussed in Section
3.6.4.4. However, for now, it is important to note that regardless of the source of funding, it will
take a large amount of capital investment in order for the colloidal micelle vaccine to reach the
market, as will be discussed in the following section.
3.6.3.6 Investment Required
The total investment required to get the Irvine vaccine to the market depends primarily
upon the volume of production expected. Predicting the market demand for any novel product,
however, is difficult, thereby making necessary investment requirements also difficult to
determine. According to the cost analysis discussed earlier in this section, if the colloidal
imicelle vaccine manufacturers encounter low demand and sell approximately 68,000 doses in the
first year, then the average unit price that year, assuming the same cost model demonstrated in
Table 5, will be $3,620.92, leading to a yearly cost of $247M. However, if the vaccine
encounters high demand initially (10%), then the company would have the capability of selling
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an average of 680,000 doses at a cost of $891.50 per unit, giving a total yearly cost of about
$606M. The best financial plan for a company marketing the colloidal micelle vaccine would
most likely be to expect low demand in year, and to produce to that effect, and then gage how the
market responds to the product. After the first year, the company can increase production to
meet the customers' needs. Therefore, investments to cover production volume of at least
68,000 doses are necessary for the colloidal vaccine to reach the market, requiring approximately
$300M initially, although some of this investment could potentially come from initial vaccine
sales.
3.6.4 Business Plan
As a result of the economic and market challenges associated with bringing a colloidal
micelle vaccine to the market, typically only major international vaccine manufacturers,
particularly those shown in Figure 9, have the resources necessary to produce new vaccines.
And with the development of new bacterial and viral vaccines, recombinant vaccines, and other
new technologies that require the need to scale up production and heavily invest in capacity and
compliance, a number of the local producers have disappeared or been acquired by larger
pharmaceutical firms.5- 86 As such, the feasible business plans for successfully marketing the
colloidal micelle vaccine are few. These possibilities will be examined throughout this section,
and an optimal plan will be set forward and discussed.
3.6.4.1 Vaccine Companies Today
The contributions of various U.S. networks to the vaccine development process are
shown in Table 7. Note that only large companies have thus far been highly successful in both
manufacturing and receiving licensure for vaccine products.
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Table 7: Relative contributions of various agencies to vaccine research and development93
RESEARCH DEVELOPMIENT
Basic /Related Targeted Process Clinical Manufacture Postlicenure
Studies
NIH +++ +++ ++
CDI ++
FDA + 4 + +
DOD + + + +
USAID +
State +  +
Large company + -++ +++ ++ ++ +++Small company + - + t _ 
Academia + + - + +
NGOs + +
Abbreviations NIH, National Institutes of Health; CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administra-
tion: DOD, Department of Defense; USAID, US Agency for International Development; NGCO, nongovernmental organization.
'Relative contribution: + + major: + +, intermediate: +, minor: , anes bv companv
Apart from the success of major manufacturers today, however, several other possibilities
for development of future vaccines are available, including the potential influence of major
Pharma and biotech companies. 5' Furthermore, while large, multinational firms are still most
likely to be the primary source of newly developed vaccines for the time being, emerging
companies abroad may become prominent in the long-term as the primary suppliers of the lower-
priced vaccines.' 8 Thus, despite the concentrated arrangement of vaccine companies today,
some predict that in the future, there will be fewer "broad line" vaccine manufacturers and more
smaller companies targeting only specific diseases and antigens. However, in the near future,
production, control, and regulatory constraints keep barriers to entry high in the area of
vaccines.94
3.6.4.2 Cancer Vaccine Companies
Regardless of the barriers to entry in the vaccine industry, over 60 companies globally are
currently working on cancer vaccine development. While there are no approved cancer vaccines
on the market to date, 64 companies are involved in clinical development of cancer vaccines, and
80 percent of these companies are small biotechnology firms.9 - Examples of small
biotechnology firms that are focused on cancer vaccines include Biomira, Corixa Corp,
Dendreon, Progenics Pharmaceuticals, Vical, and CancerVax. However, though cancer vaccines
are definitely the "sizzle" in the vaccine world,2 °many of the small public start-up vaccine
companies have suffered on the stock market. Figure 26 shows the 5-year earning charts for
several small cancer vaccine companies as of April 25, 2005.
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Figure 26:: Earning charts as of April 25, 2005 for several small, public vaccine companies,
including (clockwise from upper left) Corixa, CancerVax, Vical, and Biomira.9 6
Although the stock market in general suffered in 2001, small cancer vaccine companies
took a more serious hit than the majority of companies, as shown in Figure 26. In contrast, the
earnings charts for the four primary vaccine companies, Wyeth, Merck, Aventis, and
GlaxoSmithKline, are shown in Figure 27. While earnings dropped in 2001 for all of the
companies, recovery has been made for most, and earnings have been steadily rising for the past
couple of years for all four companies.
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Figure 27: Earning charts for the major vaccine companies as of April 25, 2005, including
(clockwise from upper left) GlaxoSmithKline, Wyeth, Merck, and Aventis. 96
The consistency and reliability of large pharmaceutical companies can be an appealing
alternative to forming a start-up company. However, there are also high rewards for forming
such a new company. The advantages and disadvantages will have to be weighed to determine
the best business plan for the colloidal micelle vaccine. As a start, however, the next section will
focus on Corixa Corp, a small pharmaceutical company that focuses much of its attention on
cancer vaccine research. Through analysis of the company, many conclusions can be drawn
regarding an acceptable next step for the novel Irvine vaccine.
3.6.4.3 Focus on Corixa Corp
Corixa Corp is a small Seattle-based biotechnology firm. As mentioned in section
3.6.1.3, their U.S. Patent No. 6,312,731 broadly covers parts of the Irvine vaccine, and some sort
of co-licensing agreements will most likely have to be made with the company in order for the
irvine vaccine to make it to the market. Funding for Corixa has come from the NIH and several
venture capitalist groups, including BankAmerica Ventures, Frazier Healthcare Ventures, and
Interwest Partners. 9 7 98
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Corixa currently has nine products in clinical trials (five for cancer vaccines), and several
others in pre-clinical development. They also have several vaccine adjuvants available for sale
in Europe and South America, although none have been approved by the FDA for use in the
United States.9 One of Corixa's key developments is Melacine, a vaccine for patients suffering
from melanoma. Already approved for use in Canada, the company submitted the vaccine for
FDA approval in 2002. The FDA, however, had required that a new 8-10 year study be
performed before the commercial use of Melacine in the United States can be approved.9 9 The
company has shown no signs of beginning new trials, and the product has been licensed to
Schering-Plough, who serves to market Melacine in Canada. 0° °
As with the development of Melacine, Corixa has partnered at least 16 different
companies throughout the years for the development and marketing of various new products.
These partnerships, according to the company, are the key to a successful commercialization
strategy. The company website summarizes Corixa's business strategy with the following:
-'Corixa partner vWith organizations that bring complementarv skills, technologies and resources
to bear at important points in the development lihf cycle. This strategy allows the compan to
increase the pace of commercial development, while retaining a significant portion f potential
dcownstream revlenute.9 7" As the website states further, "the complexity, duration and cost
associated with drug discovery and development do not reward lone rangers." Therefore, Corixa
focuses on partnering with other biotechnology firms, such as GlaxoSmithKline and Aventis, in
order to increase the probability of bringing various pharmaceutical products to the market.
Unfortunately, since its inception, Corixa has suffered from "significant operating losses
in each year. 0°° " When the company partnered with Incyte Pharmaceuticals Inc. in February of
2000, Corixa stock soared, trading for as high as $66.63. 10t However, stock prices are now down
to around $3.00. For the year 2004, Corixa's total revenue was about $25M, compared with
$35M for 2003. As of December 31, 2004, Corixa reported $116.2M in cash, cash equivalents,
and investments. In contrast, as of September 30, 2003, Corixa reported $200.9M in cash, cash
equivalents and investments.
Significantly, Corixa announced publicly on April 29 th of this year that GlaxoSmithKline
would be acquiring the company for approximately $300M. The deal is expected to close in the
third quarter of 2005. 97 While Corixa's market exit can be viewed as a success both
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scientifically and socially, it is important to note from this case study that the company struggled
financially from its inception to its exit.
3.6.4.4 Proposed Business Plan
As discussed in section 3.6.3, if the colloidal micelle vaccine is approved by the FDA and
brought to the market, significant profits could be made. However, obtaining the finances
necessary to form a new company is a significant challenge. In addition, based upon the
economic results for several start-up cancer vaccine companies, including Corixa Corp, it seems
that starting a new company based purely on the colloidal micelle vaccine, while possible, would
be an impractical business solution. The best solution seems to be to at least partner with a
larger firm, such as GlaxoSmithKline (GSK) or Aventis, that has shown much better earnings
throughout the last five years and is more capable of both financing the necessary research and
development as well as manufacturing the vaccine on a large scale. As co-licensing with Corixa
Corp, now part of GSK, would be necessary anyways for intellectual property reasons,
partnering with the GSK is most likely an ideal business plan. Simply licensing the invention to
GSK would certainly be the easiest solution, although there is definitely potential to create a new
small company under the guidance of GSK or a similar large parent company. The following
contains an outline for a small company manufacturing the vaccine under the guidance of GSK.
Whether simply a branch of GSK or an independent company with financial and licensing ties to
GSK, the business outline should be essentially the same.
The general flow of materials and information for the given business plan is shown in
Figure 28. As demonstrated, the supply of materials would most likely come from a distribution
company seeking profits from the vaccine. The colloidal micelle vaccine would then be
produced under the direction of the parent company, GSK for instance. Both the smaller branch
of GSK and the overall company would extract value from the product through the publicity
associated with a successful cancer vaccine and the profits that are taken in. The vaccine would
be distributed to doctors and hospitals, who could obtain value from the vaccine because it
requires less time per patient and should be more effective than standard cancer treatments.
Finally, the patients who receive the vaccine would value it as a result of the high efficacy and
the few side effects associated with the vaccine.
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Figure 28: Flow chart for materials and information for production of Irvine vaccine.
Expected value for each step is demonstrated in the colored boxes to the right.
Obviously, there are still several challenges associated with the suggested business
solution. In particular, securing investors at the correct time, conducting clinical trials, getting
the vaccine registered, etc., can take great amounts of time and planning. Ideally, the developers
of the Irvine vaccine could partner with GSK in a timely manner such that the most of the costs
associated with vaccine development could be covered by the parent company. A possible
timeline for development of the vaccine is shown in Figure 29.
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Figure 29: Possible business timeline for development of the Irvine vaccine.
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If a timeline similar to that shown in Figure 29 is followed, then the Irvine vaccine will have the
potential to be successfully marketed and sold.
3.7 Competing Technologies
While the Irvine vaccination method may appear to be highly marketable, as there are no
approved therapeutic cancer vaccines on the market, it is possible that other developing
technologies, such as DNA vaccines, live viral vectors, DC-based vaccines, and basic protein
and peptide vaccines, may become highly commercialized at the same time as the colloidal
micelle vaccine and thus lower the overall marketability of the device. These alternate
promising vaccination strategies for cancer are thus discussed in the rest of this section.
3.7.1 DNA Vaccines
The DNA vaccine is made up of a gene encoding a specific cancer antigen that is
manipulated from a foreign agent, such as a bacterium or virus, to form a strong eukaryotic or
viral promoter. This promoter is then integrated into a plasmid vector. The vaccine can be either
delivered as naked DNA or attached to an adjuvant, liposome, or bacterial vector. Injection of
the complex directly into patient cells allows the antigen to be transcribed, translated, and
expressed such that APCs can display the antigen on their surface and thus lead to the desired
immune response. Because DNA vaccines lead to the synthesis of foreign proteins inside the
patient's own cells, the immune system is immediately responsive. As a result of the mode of
processing, the expressed protein is presented to the immune system both by the MHC class I
pathway, resulting in CTL induction, and the MHC class 11 pathway, leading to TH cell
responses.
3.7.1.1 Advantages and Disadvantages of DNA Vaccines
DNA vaccines are extremely promising because they are easy to produce and have
versatile engineering possibilities if targeting or co-stimulatory genes are built into the vaccine.48
DNA vaccines are also advantageous because they have the potential to induce prolonged
antigen expression by continuously expressing the tumor antigen from DNA-infected cells.24 In
addition, DNA vaccines could circumvent both pre-existing immunity and immuno-dominance,
both of which tend to be dominating concerns in other types of cancer vaccines.3"
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On the other hand, however, DNA vaccines do have several disadvantages. The largest
lrawback to DNA cancer vaccines is that thus far they have shown no efficacy in human clinical
trials. Aside from this major concern, the issue of most significance to investigators is the
possibility that injected DNA will be integrated into the host genome and cause cellular
transformation, potentially calusing cancer through the alterations of normal DNA.23
.3.7.1.2 Comparison of the Irvine Vaccine to DNA Vaccines
If effective, DNA vaccines could be the most serious competitors of the Irvine vaccine, as
these vaccines are more robust and can thus be more easily produced and stored than the
colloidal micelle vaccine. In addition, DNA vaccines have the potential to cost significantly less
than the Irvine vaccine because DNA is less complicated to produce than proteins, for which
[)NA is a mere stepping stone in the overall production process. However, price estimates of the
colloidal micelle vaccine, as discussed in section 3.6.3.3, seem to be fairly competitive with
DNA estimates. And, although still in the pre-clinical stages, the colloidal micelle vaccine
shows more promising signs of efficacy.
3.7.2 Live Viral Vectors
In live viral vector vaccines, attenuated viruses act as carriers (vectors) of foreign DNA
encoding an antigen in order to express the antigen intracellularly. The attenuated vaccines are
generally developed by deleting genes encoding one or more metabolic factors from wild-type
pathogens so that recombinant attenuated vaccines are specifically engineered to be more safe
than injecting the virus directly. Once the patient is infected with the virus, the body's immune
system should respond to the invasion of a foreign pathogen. Eventually, the antigen carried by
the vector is expressed, and the patient is protected from infection. 22 Thus far, quite a few
viruses have been studied for use as recombinant vaccine vectors, such as attenuated, replication-
deficient poxviruses (such as modified vaccinia Ankara, fowlpox and canarypox), adenovirus,
herpesviruses arid Venezuelan equine encephalitis. 48
3.7.2.1 Advantages and Disadvantages of Live Viral Vectors
Viral vector vaccines are promising because they have the potential to have extremely
high immunogenicity as a result of their ability to induce immunological 'danger' signals at sites
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of infection and thus directly infect APCs.48 In addition, viral vectors can infect a wide range of
human cell types because fusion of antigen genes to different targeting sequences can direct the
antigens to various viral components and thus to different host cell components. 1 Viral vectors
also have the potential to allow for the expression of several therapeutic antigens in one vector.23
Finally, numerous foreign antigens have already been examined for use in a variety of viral
vectors, leading to hundreds of possible antigen/vector combinations. 2'
Despite these advantages, safety is a big issue concerning the use of viral vectors, as is
large-scale production; Chiron's influenza vaccine is one example of the difficulties that can
arise when using viral vectors. Another important barrier to virus-based vaccination is the
presence of neutralizing antibodies in pre-exposed or prevaccinated individuals, which reduces
the ability of the virus to immunize.23 Similarly, individuals who have not been previously
exposed to the virus can produce neutralizing antibodies after the first vaccination, which then
prevents later vaccination with the same vector.4 8 Other features of viruses that can weaken their
effectiveness as vaccine vectors include the presence of virally encoded inhibitors of immunity
that can block the processing and presentation of antigen.30
3.7.2.2 Comparison of the Irvine Vaccine to Live Viral Vectors
The novel vaccine being developed in Irvine's laboratory has significantly different
limitations than viral vector vaccines. The advantages of viral vectors over the colloidal micelle
vaccine include their efficacy in delivery antigen to the DCs; 99%/ of DNA in virus-based
vaccines would be expected to arrive at the DCs, while as low as 1% of the antigen delivered by
synthetic methods is effective in reaching the body's DCs. 29 In addition, viral vaccines are more
diverse in their possibilities. However, the colloidal micelle vaccine, unlike viral vaccines,
should have the potential to be used more than once in a patient without regard for neutralizing
antibodies that already exist in the body. In addition, the Irvine vaccine is expected to be much
safer than viral vector vaccines.
3.7.3 Dendritic Cell (DC) Vaccines
DC-based vaccines are one of the newest developments in cancer vaccine design. To
produce DC vaccines, dendritic cells are taken from the blood of a cancer patient through
leukapheresis. In the laboratory, the DCs are stimulated with the patient's own cancer antigens;
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DCs can be loaded with autologous or allogeneic tumors, apoptotic bodies, tumor lysates, tumor
RNA, and tumor DNA. 1' 2 The DCs are then grown in Petri dishes and re-injected into the
patient. Once injected, DCs carry the antigen to the T-cells and thus activate the immune system
in order to initiate a response against the tumor antigen.48
3.7.3.1 Advantages and Disadvantages of DC Vaccines
The benefits of DC vaccines are that they have the potential to provide high
immunogenicity, they offer several means of antigen loading, their potency can be enhanced by
transducing DC-activating genes, and they have the possibility to utilize all potential tumor
antigens by DC-tumor fusion or DNA transfection. 48
Unfortunately, a key drawback to the DC vaccine approach is that the peptides reside on
the DC surface for only hours, and therefore may not trigger the immune response for a
sufficient period of time. 23 The efficacy of DC vaccines is also questionable because the degree
of maturation induced in vitro is not equivalent to that in vivo; thus, it has been demonstrated
that most DCs do not travel to draining lymph nodes after in vitro loading. In addition, there is a
high potential for autoimmunity when using DC vaccines. A final concern is that individualized
cell processing is required for DC vaccines, which severely lengthens the time required for
manufacturing and significantly increases the overall cost of the vaccine, making DC-based
vaccines only a possibility for wealthy industrial countries.4 8
3.7.3.2 Comparison of the Irvine Vaccine to DC Vaccines
Like typical DC vaccines, the novel vaccine being developed in Irvine's laboratory is
meant to trigger the normal immune response through use of the body's own dendritic cells.
Thus, the colloidal micelle vaccine should, similar to DC vaccines, have the potential to provide
high immunogenicity. The Irvine vaccine should, however, be advantageous over manipulated
DC vaccines because it should trigger a continuous release of proteins, it allows DCs to mature
in vivo, and it does not require individual cell processing, unlike typical DC vaccines. One
aspect by which DC-based vaccines have the potential to be superior is that theoretically,
investigators woul d have better control over the activation of DCs through laboratory
manipulation.
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3.7.4 Protein and Peptide Vaccines
When the molecular basis of tumor antigens is identified, an immunological response can
be obtained using a simple peptide or protein. The candidate epitope can be a functional
oncogene required for tumor cell growth, a cell surface molecule specific to a given tumor
phenotype, or a potential "universal market of tumor cell growth," such as telomerase.2 4 For this
type of vaccine, a peptide or protein is administered either alone, such as the MAGE peptide or
the heat shock protein, or in combination with an adjuvant or a cytokine, such as the Freud
adjuvant or IL-2., correspondingly. 27
3.7.4. 1 Advantages and Disadvantages of Protein and Peptide Vaccines
Peptide and protein vaccines are advantageous because they are very easy to produce and
can be readily made under good manufacturing practices, which allows for low production costs
and rapid translation of laboratory studies into clinical trials. In addition, because protein and
peptide vaccines are relatively simple, they are believed to be an extremely safe vaccination
method.24
Peptide/protein vaccination strategies have several potential drawbacks, however, and
peptide vaccines in particular have several disadvantages. Both protein and peptide vaccines are
often weakly immunogenic. In addition, peptides vaccines may induce tolerance, and DC-
mediated presentation may induce only a limited or ineffective antitumor response. 24 Peptide
vaccines also face the danger of tumor mutagenesis and immune evasion.: 9 Finally, peptide
vaccines are not highly appealing for clinical use, as they can only be used in patients with
particular HLA types.2 8
3.7.4.2 Comparison of the Irvine Vaccine to Protein and Peptide Vaccines
Because the colloidal micelle vaccine uses a protein antigen, it should be more useful
than peptide vaccines because, like protein vaccines, it should work for all HLA types. The
novel Irvine vaccine should also be much more immunogenic than a protein/peptide vaccine
because of the chemoattractant and maturation factors included in the vaccine. However,
protein/peptide vaccines are slightly advantageous to the extent that they are easier to produce
and manufacture on a large scale than the more complicated Irvine vaccine.
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.3.7.5 Effect of Competing Technologies on the Colloidal Micelle Vaccine
While there are over 215 different cancer vaccines being developed,20 none have yet been
approved by the FDA. This hesitancy to approve cancer vaccines is related to the lack of success
in most clinical trials. As summarized by Rosenberg in a 2004 review of clinical trials believed
to be representative of the majority of published trials to date, only a 3.3% overall objective
response rate was documented for all types of cancer vaccines. °3 This ineffectiveness could
potentially allow newly developing vaccines, such as the colloidal micelle vaccine, a better
prospect for getting a hold on the market if effective. However, developing an effective cancer
vaccine, as demonstrated by numerous investigators of competing technologies, is a difficult
task; achieving efficacy with the colloidal micelle vaccine could be a bigger challenge than it
seems.
Furthermore, although clinical trials of the three competing vaccination strategies have
not been demonstrated to be effective as of yet, the vaccines can still pose at least a slight threat
to the vaccine method being developed in Irvine's laboratory, if only because they have come
further along in the development path. While most cancer vaccines are still either in preclinical
stages or in phase I and II trials, some vaccines, such as the protein vaccine Theratope and the
viral HPV quadravalent vaccine, have made it to Phase III trials. 0° 4 As demonstrated in Table 2,
the time required for a successful vaccine to make it to the market is at least 10 years, with each
phase of clinical trials taking a significant portion of those 10 years. Therefore, the further along
the timeline of development that a vaccine is, the higher probability the vaccine has for being
successful in the market.' s Therefore, in order to be competitive in the cancer market, the
colloidal micelle vaccine must get through the pre-clinical work quickly and continue on to
Phase I studies.
3.8 Challenges
Unfortunately, as suggested throughout this paper, non-scientific hindrances can be some
of the most substantial barriers to achieving the full application potential of new vaccination
technologies.' 3 Apart from the issues, such as financing the vaccine, that have already been
discussed, there are several additional challenges associated with bringing any new vaccine to
the market. Specifically, ensuring that the vaccine is available globally, upholding ethical
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standards, and overcoming the public fear of vaccination, can create considerable adversity
during vaccine development.
3.8.1 Making the Vaccine Available Globally
The mismatch between disease burden and investment is a significant issue in the
development of vaccines. As discussed in section 3.6.3.4, neither the public, nor the private
sector, want to make an investment if the risks of failure are high. Ideally, the public sector
would avoid all risk and only buy a product once it is developed, in high demand, and available
at a reasonable price. In contrast, in this idealized world, the private sector would only invest
once there were solid, high market commitments.' 8 As a result of both this mismatch and the
economic burden associated with obtaining vaccines, there is a growing "equity gap" in vaccine
usage between rich and poor countries. a4 As recently as 1975, less than 5% of the world's
children had access to vaccines, despite immunizations being the most cost-effective health
intervention method. Programs such as the Expanded Program on Immunization (EPI) have
helped to ensure that up to 75% of children worldwide now have access to routine-coverage
vaccines. 32 However, non-routine vaccines, such as the Irvine vaccine for cancer, would most
likely not be sponsored by such programs, and reaching countries worldwide could be a
significant hurdle in development of the colloidal micelle vaccine.
Two strategies have been suggested that could be used to accelerate the development of
priority vaccines such as those for cancer. These strategies include push mechanisms, which
reduce the risks and costs of investments, and pull mechanisms, which assure a future return in
the event that the vaccine is brought to the market. Push mechanisms can include direct
financing, facilitating research, and giving tax credits for vaccine research, whereas pull
mechanisms include such procedures as accelerating the uptake of existing vaccines, providing
co-payments, and using tiered pricing.' S'5 Some of these suggested mechanisms can be seen in
Figure 30.
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4Figure 30: Typical push/pull mechanisms associated with the development of a vaccine.
Despite the suggested mechanisms through which priority vaccines can be more easily
developed, much more work is needed in order to translate the push-pull mechanisms into action.
Historically, the public sector has invested primarily in early stage push mechanisms, while very
little was contributed to the pull mechanisms from any source. More recently, however,
organizations such as the Global Alliance for Vaccines and Immunization (GAVI) have begun to
play a part in the pull mechanisms involved in vaccine development. GAVI, launched in 2000,
is a partnership that includes national governments, UNICEF, WHO, The World Bank Group,
the Bill & Melinda Gates foundation and other foundations, nongovernmental organizations, the
vaccine industry, and research and technical health institutions. The objective of GAVI is to
coordinate and revive immunization programs at international, regional, and national levels. °5
Through such foundations, in addition other push-pull mechanisms, the spread of vaccines
worldwide has the potential to become a reality.
3.8.2 The Ethics Behind Vaccine Development
Apart from ensuring that vaccines are available on a global scale, there are several ethical
concerns in developing a new vaccine. In particular, conducting clinical trials in an ethical
manner is a of utmost importance. The conduct of clinical research is guided by three principles
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that are set forth by the Belmont Report: respect for persons, beneficence, and justice. Thus,
researchers involved in clinical trials must, among other things, use informed consent, maximize
the potential benefits to the subjects while minimizing risk, and treat all groups of people equally
and fairly.' 10 6
One of the issues of most debate regarding clinical trials is the controversy over the
conduction of such trials in developing countries. As a result, a number of international codes of
ethics for research have been developed in order to ensure that abuse involving human subjects is
avoided. There are, however, still several disagreements associated with clinical trials.
Researchers debate whether there is one international standard for informed consent, if there is a
role for community consultation and consent, where clinical trials should first be conducted, and
what is owed to research participants at the conclusion of the study.10 6 Issues such as monitoring
the safety of patients, ensuring that there is some sort of benefit for the volunteers, and whether
using a placebo is ethical when other treatments are available for the disease, are all of constant
debate in the pharmaceutical research community. 4°
3.8.3 Growing Opposition to Vaccines
Finally, the development of novel vaccines can be imperiled by the public's own fear of
such vaccines. Because vaccines have led to the "disappearance" of a number of diseases, the
need to immunize is no longer highly valued among the general public, and the adverse effects
associated with using any vaccine have become more widely perceived. 5 ' Over the past 15
years, unsubstantiated hypotheses regarding the safety of various vaccines have led to a growing
opposition to vaccines. Anti-vaccination lobbyists have spread doubts about any form of
vaccination, implying that causal health consequences, such as neurological damage,
unexplained death, and AIDS can be direct results of various vaccines.8 4 Similarly, adverse
effects associated with various vaccines, such as swelling at the site of injection, headaches,
fever, and seizure, have led the public to associate such effects with all vaccines. 2 Overcoming
this fear, in addition to the other challenges set forth in this paper, will be of great consequence
in getting the Irvine vaccine to the market.
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4.0 Conclusions
The technical, economic, and clinical challenges associated with bringing a novel
hydrogel and particle-based injectable vaccine to the market have been examined throughout this
paper. Developed in the Irvine laboratory and composed of super-assembled polymer particles
containing chemoattractant, antigen, and maturation factors, the colloidal micelle vaccine aims to
cause a tailored immune response in a patient so as to mimic the body's natural immune
response. Numerous potential applications exist for the colloidal micelle vaccine, although the
treatment of melanoma is the most probable of these applications. Research into vaccines,
particularly cancer vaccines, is a growing strategy, and the Irvine vaccine is especially exciting
because it utilizes DCs in their immature state, efficiently assembles DCs at the site of
vaccination, and provides the antigen and maturation signal in a coupled manner. The
intellectual property, manufacturing, and economics associated with bringing the vaccine to the
market have been examined. As demonstrated throughout this paper, obtaining value from the
vaccine on a large scale is possible. However, in order to do so, the developers of the Irvine
vaccine will have to follow a business plan similar to that outlined in this paper and partner with
a prominent vaccine company, such as GSK. After numerous business considerations and
challenges have been analyzed fully, a brief overview of which has been presented in this paper,
commercial development of the colloidal micelle vaccine can be a successful endeavor.
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